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ABSTRACT
UTILIZATION OF AQUEOUS RAFT SYNTHESIZED COPOLYMERS TO
IMPROVE ANTICANCER DRUG EFFICACY
by Andrew Christopher Holley
December 2014
The advent of controlled radical polymerization (CRP) techniques, along with
advancements in facile conjugation chemistry, now allow synthetic tailoring of precise,
polymeric architectures necessary for drug/gene delivery. Reversible additionfragmentation chain transfer (RAFT) polymerization and its aqueous counterpart
(aRAFT) afford quantitative control over key synthetic parameters including block
length, microstructure, and placement of structo-pendent and structo-terminal
functionality for conjugation of active agents and targeting moieties. The relevance of
water-soluble and amphiphilic (co)polymers synthesized by RAFT for in vitro delivery of
therapeutics in biological fluids is an especially attractive feature. In many cases,
polymerization, binding, conjugation, and stimulus-induced release can be accomplished
directly in aqueous media. However, specific problems, barriers, and challenges
regarding rational design of polymeric delivery systems for therapeutic siRNA still exist.
This dissertation focuses on RAFT synthesized (co)polymers as vectors and
functional constructs to overcome delivery challenges. In section I, a modular copolymer
consisting of HPMA and glutamic acid was synthesized to overcome hurdles of
endosomal escape. Glutamic acid undergoes a coil-to-helix transition at endosomal pHvalues, and these helices were stabilized with HPMA. As a proof-of-concept, the pHresponsive constructs demonstrated membrane disruption via red blood cell hemolysis
and dye release from fluorescein-loaded POPC vesicles. In section II, hydrophilic-blockii

cationic copolymers were complexed with siRNA to ascertain the structure-property
relationships governing siRNA release from block ionomer complexes (BICs). It was
determined that the stability of the complexes, which increases with increasing cationic
block length, delayed the time required to achieve gene suppression. These results
indicated that decomplexation was facilitated via an ion exchange/substitution
mechanism. In section III, AS1411, an anticancer biologic, was delivered utilizing
hydrophilic-block-cationic copolymers. The prepared BICs were found to be
monodisperse (PDIs < 0.1) and charge neutral (i.e., N:P = 1). The anti-proliferative
ability of AS1411 was then assessed utilizing hydrophilic-block-cationic copolymers as
delivery vehicles. After 72 h, AS1411 demonstrated successful cellular inhibition;
however, negligible anti-proliferative activity was witnessed when AS1411 was delivered
utilizing hydrophilic-block-cationic copolymers. This reduction in drug activity was
attributed to reduction of available drug caused by increased BIC stability as was
determined in Section II.
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CHAPTER I
INTRODUCTION
The targeted delivery of nucleic acid-based therapeutics has recently become one
of the most active areas of research in the rapidly developing field of nanomedicine.
Unprecedented advances in synthetic polymer chemistry over the last decade now allow
for precise control of macromolecular structure and thus rational design of biologicallyrelevant carriers with functional components engineered to aid in stabilization, trafficking
and stimulus-induced release of “packaged” therapeutic agents. This chapter will focus
exclusively on synthetic (co)polymers and their conjugates prepared via controlled
radical polymerization (CRP) that have potential for therapeutic delivery of small
interfering RNA (siRNA). Criteria for efficient delivery and efficient gene “knockdown”
through the RNA interference (RNAi) are presented based on current understanding of
cellular delivery pathways. Emphasis is placed on synthetic carrier structures and features
of controllable segments which lend themselves to polyplex formation, siRNA packaging,
targeting, uptake, endosomal escape, and delivery to messenger RNA (mRNA) targets.
Although research with siRNA/CRP polymers is in its infancy relative to more
mature areas of DNA therapy, rapid growth is forecasted due to fewer intra-cellular
barriers to delivery and to the structural control afforded by new synthetic techniques,
often accomplished directly in aqueous media. It is interesting to note from a historical
perspective that discoveries of the RNA interference (RNAi) pathway1 and reversible
addition-fragmentation chain transfer (RAFT) polymerization2 were both reported in
1998.

2
Rational Design of Polymer-Based Delivery Vehicles
The concept of tailoring synthetic polymer vehicles (vectors) for site-selected
delivery and release of therapeutic agents was pioneered by Ringsdorf over 35 years ago.6
He and his colleagues suggested a simple “depot” model (Figure 1) in which the
therapeutic agent could be attached in a facile manner via a hydrolytically- or
enzymatically-degradable spacer to a water-soluble, non-immunogenic (co)polymer
backbone having requisite components for complex protection, solubility and circulation
under physiological conditions. Therapeutic cargo could be trafficked either passively or
actively (the latter by including targeting moieties) to specific “depot” sites for stimulusinduced release as directed by endogenous cell components. The model was later
extended for attachment of a diagnostic component to track location of the carrier, thus
setting the stage for dual purpose theranostic (therapeutic/diagnostic) vehicles. The
concepts of this seminal model remain at the forefront of rational design strategies for
polymeric vehicles utilized for pharmaceutical delivery, including siRNA therapeutics.
However, only recently have facile polymerization and orthogonal chemistries been
developed that yield precise architectures, segment lengths, selected sizes, functionality,
and narrow molecular weight distributions required. For example, the CRP syntheses of
well-defined (co)polymers with pH-responsive, tertiary and secondary amine segments
necessary for reversible polyplex formation with polynucleotides have recently been
reported.7 More specifically, rationally-designed siRNA polyplexes with targeting
moieties have shown therapeutic potential in vitro as demonstrated by cell-specific
delivery and gene silencing via the RNAi pathway. It should be noted that despite
fundamental distinctions of nucleotide structure and trafficking,8 many of the recent
approaches to siRNA delivery have precedence in DNA delivery utilizing a variety of

3
polymer types including classical, or controlled chain growth polymers, dendrimers,
polymers from ring-opening polymerization, and those prepared from syntheticbioconjugate techniques. Nano- and micro-structured particles, micelles, polymersomes,
microemulsions, hydrogels, transition metal complexes, carbon nanotubes, and inorganic
complexes have been reported. The reader is directed to a number of comprehensive
reviews of these DNA delivery vectors.9–20

Figure 1. Components of the Ringsdorf “depot” model.

RNA Interference (RNAi)
RNA interference (RNAi) is a gene silencing effect induced by RNA duplexes
that ultimately results in messenger RNA (mRNA) cleavage, thus inhibiting expression of
target proteins. Importantly, RNAi potentially offers a pathway for therapeutic treatment
of a variety of diseases including genetic, degenerative, and viral diseases as well as
cancer.21 In a recent Chemical Society Review,22 Gaynor et al. present the mechanism of
RNAi as currently understood. A simplified seven step pathway (Figure 2) is detailed
that starts with the formation of siRNA duplexes generally 21–23 nucleotides in length
and having a two-nucleotide overhang at the 3’ end. The duplexes, which can be
prepared synthetically or by endogenous processing of longer hairpin or double-stranded
RNA (dsRNA), have precise sequences such that the antisense or “guide” strand is

4
complimentary to the target messenger RNA (mRNA) transcribed from the gene to be
“silenced.” The siRNA duplex associates with cytoplasm proteins and is trafficked to the
RNA-induced silencing complex (RISC) for removal of the sense or “passenger” strand,
thus activating the complex for target mRNA recognition and complementary binding.
RISC contains a protein with endoribonuclease activity that cleaves the mRNA backbone
specifically between nucleotides 10 and 11 relative to the 5’ end of the guide strand.
Ideally, after dissociation from the cleaved mRNA, recycled RISC can then target other
mRNA strands. For further discussion of kinetics, biodistribution, stabilization, cellular
uptake, chemical modification, possible interferon response, and off-target effects
operative in RNAi, the reader is referred to several recent reviews.21–29

Figure 2. The RNA interference (RNAi) pathway.22

5
Barriers to siRNA and General Approaches to Therapeutic Delivery
RNAi therapy has been highly touted due to its simplicity (relative to other forms
of oligonucleotide intervention) and applicability to a large number of diseases.
Advantages are that interference occurs at the translational rather than the transcriptional
level, relatively small doses of siRNA are required, and lower toxicity is generally
observed. However, efficient delivery necessitates overcoming significant barriers
(Figure 3) that stem from the physicochemical properties of siRNA and systemic
interactions during trafficking to cytoplasm targets.23–29

Figure 3. Cellular barriers to oligonucleotide delivery.21

Cellular delivery of siRNA and other polynucleotide therapeutics has been
accomplished utilizing a number of viral and non-viral vectors.10,12,19,20 Controlled
polymer-based carriers, the focus of this review, are designed to eliminate or suppress
repulsive electrostatic interactions between double stranded siRNA and the cellular
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surface.8,26,28 The formation of interpolyelectrolyte complexes (IPECs or polyplexes)
between therapeutic RNA and cationic polymer segments, not only accomplishes this, but
also may induce compaction of longer dsRNA while conferring protection from
endonucleases encountered in RNAi. Cellular entry can occur by non-specific or targeted
polyplex uptake. Wong et al. recently reviewed several pathways for endocytic uptake in
polymer-mediated gene delivery: phagocytosis, macropinocytosis, clathrin-mediated
endocytosis, caveolae-mediated endocytosis, and clathrin- and caveolae-independent
endocytosis.19 Although all of the above result in enclosure of the polyplexes within
transport vesicles formed from the plasma membrane, subsequent trafficking and
processing modes are different and the factors determining the specific pathway are not
well elucidated at this point. Most studies so far have dealt with DNA, and there are
likely to be differences between DNA and siRNA polyplex internalization based on size
and interpolyelectrolyte registry. However, there are some structural similarities that may
be identified. In general, non-specific endocytosis can be triggered by (a) chargemediated interactions of cationic polyplexes with sulfated or carboxylated glucosamine
residues on membrane-bound proteoglycans and/or (b) hydrophobic associations of
lipophilic residues on the complex with the phospholipid layers of the cell membrane.19,28
Recently, cell penetrating peptides, 5 to 40 amino acids in length with amphipathic and
cationic segments have shown potential for binding polynucleotides and facilitating
membrane translocation.30 These peptides may enter non-specifically into the
phospholipid membrane by several postulated mechanisms including: formation of
peptide-lined pores, direct penetration, transient uptake, and induced endocytosis.30
Targeted delivery is accomplished by incorporating ligands that bind to receptors
on the cell surfaces. Receptor-mediated targeting and delivery of therapeutics to specific
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cell lines has been widely studied utilizing a plethora of targeting ligands including
endogenous folate and transferrin and exogenous peptides, glycoproteins, and
antibodies.21,28,29 To date, however, only a few of these have been reported for targeted
delivery of siRNA utilizing CRP carriers.22,23,25
Once cellular uptake has occurred, the resulting polyplex-bearing vesicle may be
recycled to the surface, routed to cellular organelles, or participate in the endo-lysosomal
pathway.28 As illustrated in Figure 3, the polyplex must escape the endosome vesicles
before the latter mature to lysosomes in order to avoid enzymatic degradation. The
maturation of the early endosomes to lysosomes is accompanied by a pH reduction from
~6 to ~5.22 As such, polymers with pH responsive amine segments (pKa values from 5 to
7) have been utilized in the polyplex to act as a “proton sponge.” Protonation results in
osmotic swelling and disruption of the endosome and release or “escape” of the polyplex
to the cytoplasm.22,28 Peptides that undergo coil-to-helix transformations as pH is
lowered have also been conjugated to polymeric carriers to induce disruption of the
endosomes.21,23,25 After endosomal escape, polyplex dissociation must occur in order to
enter the RNAi pathway.28 Reduction of strength of interpolyelectrolyte complexes has
been the most common method of choice to date. Polymer architecture (linear, star,
dendrimer, branched, etc.), registry and spacing of charges, molecular weight,
amphiphilicity, reversible cross-linking and other structural characteristics can, in
principle, be altered to effect facile dissociation.21–23,28
While many laboratory and clinical studies have reported remarkable advances in
nucleic acid delivery using both classical polymers and those with designed, precise
architectures, there is a clear need for tailored siRNA delivery vehicles that are dynamic,
responding to in situ stimuli encountered in delivery to specific cell types. Given the
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large number of structural variables and possible cellular interactions identified in the
literature to date, Roth28 has proposed an “integrated mathematical modeling” approach
to rational design of delivery vehicles. His approach involves development of kinetic
models of antisense and siRNA silencing by first describing oligonucleotides and their
targets in discrete locations or ”compartments” within the cells. Differential equations
based on conservation of mass are then derived for each of the relevant species, for
example polymer-bound, free, and mRNA-hybridized siRNA in either endosome or
cytoplasmic environments. Roth has typically employed 10 species and 20 parameters,
the latter measure or derived from literature reports, to develop his models. Some
knockdown experiments in specific cell lines appear to validate these models.30
Successful implementation of such approaches can be anticipated in the future and will be
aided by rapidly evolving analytical methods capable of elucidating cellular entry and
trafficking mechanisms.
Controlled Radical Polymerization (CRP) and Therapeutic Vehicle Design
Carrier vehicles designed with criteria consistent with the Ringsdorf “depot”
model, previously introduced and shown in Figure1, possess essential modular
components: a water-soluble or amphiphilic polymer backbone, therapeutic agent binding
sites, and pendent targeting and/or diagnostic moieties. Initial progress toward optimal
design based on such models was restricted by the absence of sufficiently facile
polymerization techniques affording control over molecular weight, molecular weight
distribution, placement of structo-pendent or structo-terminal reactive functional groups,
polymer architecture (blocks, stars, etc.), and solubility. As controlled radical
polymerization (CRP) techniques, including stable free radical polymerization (SFRP),30
atom transfer radical polymerization (ATRP),31 and RAFT32–34 have evolved during the

9
last few years, additional tools for rational design of delivery vectors with the above
requisite parameters have become available. RAFT and more specifically its aqueous
counterpart aqueous reversible addition-fragmentation chain transfer (aRAFT)4,5,35 are
arguably the most relevant of the known CRP techniques for preparing delivery vehicles
for use in biological fluids. Not only are these particularly versatile for polymerizing a
wide range of charged and reactive monomers, in many cases polymerization,
conjugation, therapeutic loading, targeted delivery, and stimuli-responsive release can all
be accomplished directly in aqueous media.35

Figure 4. Key steps in formation of homo- and block copolymers via RAFT
polymerization.

Key steps in the RAFT polymerization process, first proposed by the CSIRO
group2 and later adapted specifically for water,4,5 are shown in Figure 4 in order to
illustrate the method’s utility for synthesizing modular, water-soluble therapeutic delivery
vehicles discussed in this review. RAFT polymerization is a degenerative chain transfer
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process that begins in step I, Figure 4 when an initiator, for example a water-soluble
diazo initiator, decomposes to yield a primary radical, R•, which then adds to a watersoluble monomer 1. In step II, a chain transfer agent (CTA), a thiocarbonylthio
compound, reacts with the primary oligomeric radical to produce an intermediate radical
that subsequently eliminates R• which in turn adds to monomer 1. The CTA is key to
control of molecular weight and ”livingness“ of the RAFT process and various
thiocarbonylthio species including dithioesters, xanthates, dithiocarbamates, and
trithiocarbonates have been utilized.32–34 The degree of stabilization of the intermediate
radicals in steps II and III of Figure 4 depends on the nature of Z as does the rate of R• or
kinetic chain scission from the intermediate for subsequent addition to monomer 1.
Active (propagating) radicals eventually reach equilibrium with dormant chains, termed
macroCTAs. The reversible nature of the degenerative process, the equilibrium favoring
the dormant chains, and the apparent inability of the intermediate radical to add to
monomer result in the polymerization having a “living” nature with degree of
polymerization increasing linearly with conversion. MacoCTAs can be extended, for
example, by the sequential addition of a second water-soluble monomer as shown in step
III of Figure 4, resulting in the formation of stimuli-responsive block copolymers.7,35
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Figure 5. Varying architectures from CRP techniques amenable to siRNA binding.

An important advantage of RAFT and other CRP polymerization techniques is the
ability to prepare well-defined polymers with specified architectures (Figure 5). Of
interest to siRNA therapeutics are diblock, triblock, brush, and star architectures prepared
from amine-functional monomers that can be synthesized via aRAFT directly in water
without the need for protecting groups.7 R and Z functionality can be altered to allow
structural variation as well as facile post-polymerization reactions.35 The nature of the
segments and the molecular weight-dependent hydrodynamic volume under aqueous
conditions, in principle, can be critically controlled by selecting from a wide variety of
water-soluble monomers,7,35 designing CTAs and their conjugates,36 and specifying the
monomer/CTA ratios.7,33–36 As detailed later, packaging and protection from enzymatic
degradation have recently been accomplished by direct, molecular level complexation of
siRNA with specified segments (for example those with cationic charges) or those
presented on nano size, self-assembled complexes (e.g., micelles, vesicles, polymersomes
and their conjugates and crosslinked versions). As mentioned previously, secondary and
tertiary amine-containing segments are thought to elicit endosomal disruption and
polyplex release by taking advantage of the “proton sponge” or buffering effect. For
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example, interpolyelectrolyte complexes between siRNA and PDMAPMA (poly(3-(N,Ndimethylamino)-propyl methacrylamide)) (or other protonated tertiary amine segments of
block copolymers)37–44 can be prepared with varied nitrogen-to-phosphate (N/P) ratios,
affecting not only solubility but also cell entry by non-specific endocytosis and eventual
release from the endosome. Neutral, water-soluble monomers such as N,Ndimethylacrylamide (DMA)45–48 or N-(2-hydroxypropyl)-methacrylamide (HPMA)14,49–62
can be copolymerized statistically or as blocks in order to maintain water solubility and
prevent rapid clearance from the blood stream. Amphiphilicity can be adjusted by adding
hydrophobic monomers (e.g., butyl acrylate38,39,63) or those responsive to temperature (Nisopropylacrylamide (NIPAM))64 or pH (secondary and tertiary amine-containing
monomers).37–44 AB diblock or ABA triblock systems of the type, shown in Figure 5, can
be prepared utilizing dithioester or trithiocarbonate CTAs that have near-perfect end
group functionality since the R group of the initiator and that of the CTA are identical.
Such telechelic end groups can play important roles in attaching moieties for targeted
delivery or for attaching diagnostic agents. Reactive functionalities, such as active esters,
exchangeable disulfides, and primary amines, can also be readily accommodated by
copolymerizing functional monomers via RAFT.7,35 A number of recent papers and
reviews discuss facile chemical or bioconjugation methods utilizing reactive monomers
or CTAs with appropriate functionality (Figure 6).13,42,65–71 Notable milestones allowing
the construction of delivery vehicles were the first controlled polymer syntheses by
Scales, Convertine, York et al. of the hydrophilic monomers DMA, HPMA, NIPAM and
the protonated (cationic) DMAEMA, DMAPMA, and APMA monomers (Figure 6) via
aRAFT polymerization.45,52,72,73 Though beyond the scope of this chapter, the reader is
referred to recent reviews of post-polymerization modification methods including
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orthogonal “click” chemistries which have been or can potentially be utilized in
delivery.66,74–89
Linear Polymer Vehicles
Literature reports of linear homopolymers with controlled structures utilized for
gene delivery are almost exclusively on P(DMAEMA) synthesized via RAFT or
ATRP.90–97 However, as previously mentioned, complexes must be cationically-charged
overall to maintain particle dispersion. Although this and favorable interactions at the
cell surface promote uptake, problems of nucleotide release from the interpolyelectrolyte
complex later in the process affect efficiency of delivery.98,99

Figure 6. Reactive monomers and functional groups utilized for delivery vehicles
prepared via RAFT Polymerization.

Perhaps the most widely studied systems for the delivery of siRNA have been
block copolymers comprised of hydrophilic and cationic segments.98,100–102 These
copolymers can form near-neutral interpolyelectrolyte complexes with negatively charged
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siRNA and have the added benefit of remaining soluble and stable in solution. However,
while the hydrophilic block can increase stability/shielding and circulation time, it has
also been shown to decrease uptake as compared to its positively charged
counterparts.98,103 To combat this problem, York et al. utilized targeting entities for
receptor-mediated endocytosis.42 Copolymers containing a cationic block of DMAPMA
and a hydrophilic block of HPMA-s-APMA were synthesized for siRNA delivery (Figure
7). The APMA (N-(3-aminopropyl)methacrylamide hydrochloride) monomer has primary
amine functionality for attaching a targeting group. These monomers were polymerized
under buffered, aqueous RAFT conditions yielding copolymers of ~ 50 kDa with narrow
polydispersity index (PDI) values of ~1.1. Folic acid, a well-known and extensively
studied targeting group moiety,104–108 was conjugated to the polymers via postpolymerization modification of the primary amines of APMA with efficiencies of > 80 %.
The resulting targeted copolymer was then complexed with siRNA to yield near-neutral
sterically protected complexes ~ 15 nm in diameter. These complexes were incubated
with cell lines that expressed both high levels (KB cells) and low levels (A549 cells) of
folic acid receptors. The targeted complexes showed high selectivity for KB cells and
60% knockdown of the gene coding for human Survivin.

15

Figure 7.Poly[ (HPMA-statistical-APMA)-block-DMAPMA] copolymers complexed
with siRNA for targeted gene delivery.43

Folic acid serves as an excellent moiety to serve as a cellular targeting group, but
there have been a few methods which utilize an alternative approach to promote cellular
recognition. Utilizing a PEG macroCTA, Schultz and coworkers prepared poly(GPMA)
which incorporated FAB antibody fragments at the α-terminus. These fragments targeted
the HER2 receptor, a member of the epidermal growth factor family that is overexpressed
in one-third of breast cancers, and cellular recognition was increased by 10-fold. As a
consequence, a major reduction in mRNA and protein levels (> 90%) was achieved.
Alternatively, mannose and cholesterol have been conjugated to RAFT synthesized block
copolymers, and while these targeting ligands promoted efficacious delivery, these
systems warrant further insight as the design of these systems provides methods to
overcome additional barriers (vide infra).
One of the most significant bottlenecks in the delivery of siRNA to cells is release
from endosomal compartments after uptake.16,109–111 One strategy has focused on the
post-polymerization conjugation of endolytic agents to the hydrophilic block of these
copolymers.111 However, even with the advent of facile and quantitative chemistries in
recent years,75,78,84,88,112,113 such post-polymerization modifications involving
macromolecular species can be inefficient and produce undesired by-products. Both
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quantifying yields and product characterization can prove difficult.114 Therefore, direct
polymerization of CRP monomers capable of undergoing stimuli responsive transitions to
“unmask” endolytic properties, such as proton sponges or hydrophobic, membranedisrupting moieties, is an attractive approach.
Convertine et al. designed an endolytic copolymer delivery system that contained
a block of 2-(N,N-dimethylamino)-ethyl methacrylate (DMAEMA) for complexation
with siRNA and an ampholyte block containing butyl methacrylate (BMA), DMAEMA,
and poly(propylacrylic acid) (PAA) to act as both a shielding/stabilizing and pHresponsive block.39 The RAFT- synthesized terpolymers ranged in molecular weight
from 16 kDa to 20 kDa with moderate PDIs (1.45–1.58). Despite the statistical nature of
the hydrophobic block, DMAEMA and PAA were chosen to be 1:1 for neutrality, while
BMA was varied to modify hydrophobic content. At physiological pH, no higher ordered
structures were formed prior to the addition of siRNA. At N:P ratios of 1:1, only large
aggregates were identified by dynamic light scattering (DLS), with a reduction in particle
size at increasing charge ratios. Particle sizes ranged from 85–236 nm with the highest
BMA content (48 mol%) giving rise to the smallest particles at N:P ratios of 4:1. Despite
the higher nitrogen content, surface charge of these particles remained near neutral. The
endolytic activities of these copolymers and IPECs were investigated using a red blood
cell hemolysis assay at varying pH values, representing physiological conditions, early
endosome, and late endosome. At physiological pH, no endolytic activity was observed
due to the charge neutrality of the ampholyte block. Polymers containing the most BMA
content demonstrated the greatest degree of hemoglobin release at both early and late
endosomal pH. Upon acidification of the endosomal compartment, it is predicted that the
carboxylic acid residues are protonated, resulting in a more hydrophobic block with an
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overall net positive charge that is likely to interact with the membrane. Knockdown of
GAPDH (glyceraldehyde 3-phosphate dehydrogenase – an enzyme that catalyzes
glycolysis and is implicated in several non-metabolic processes, including transcription
activation, initiation of apoptosis and ER to Golgi vesicle shuttling) was investigated in
HeLa cells and ranged between 50–80 % depending on the polymer and formulation.
They have further modified these systems to maintain endosomolytic capability,
but also, to produce polymeric carriers that offer neutral delivery of siRNA.115 A thiolated
siRNA targeting GAPDH was conjugated to poly[HPMA-co-PDSMA)-block-(PAA-coDMAEMA-co-BMA)] (Figure 8) via a pendent disulfide exchange in the PDSMA block.
The second block confers endosomolytic capability, and siRNA release occurs via
intracellular reduction with glutathione. Under optimized conditions, a 90 % reduction in
mRNA and a 60 % reduction in protein levels were achieved after 48 h. These researchers
have been prolific in designing these systems, and many reports utilize the
PAA/DMAEMA/BMA combination to achieve endosomal escape.
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Figure 8. Preparation of poly[(HPMA-co-PDSMA)-b-(PAA-co-DMAEMA-co-BMA)]
polymeric carriers for neutral delivery of siRNA.115

While most polymeric vehicles are designed to overcome delivery barriers, only
one report focuses both on delivery challenges as well as economic viability. Reineke and
coworkers116 prepared poly(trehalose-b-AEMA) copolymers, and the rationale behind
these constructs was to solve long-term storage of siRNA-polymer complexes. Trehalose,
a disaccharide consisting of glucose, protects cells during oxidative stress and freezing,
and it aids in cryptobiosis. The primary amine block AEMA serves to bind siRNA, while
the trahalose segments confers long-term stability. Copolymer-siRNA complexes were
reported to retain potency after lyophilization as demonstrated via luminescence assays
on U-87 cells containing Gaussia Luciferase. Modest gene knockdown was observed for
these systems (~ 60% reduced protein expression), but the fact that these systems
remained active after long-term freezing (1 month) is remarkable.
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Polymer Micelle Vehicles
The complexation of siRNA with cationic polymers results in spontaneous
assembly of IPECs. It is known from the literature that the resultant size and distribution
of these complexes is highly dependent upon the length of the charged segments, the total
length of the polymer, and the conditions under which they are prepared.7,117–124 Scales et
al. have shown that in particular instances, a single siRNA molecule can be surrounded
by multiple polymers, significantly limiting the therapeutic loading of these types of
vectors.41 Ideally, the incorporation of multiple siRNAs per polymer complex is
desirable to increase the therapeutic efficiency while maintaining control over the size,
shape, and distribution of the carrier.
One way to accomplish this is by the formation of the vehicle before loading the
therapeutic agent. The formation of well-defined micelles and vesicles from polymers
prepared via controlled polymerization methods is well established.7,67,73,100,117–122,124–140
In addition to allowing for control over the size and size distribution of the vehicle, the
use of micelles/vesicles as gene delivery vehicles also can mitigate toxicity. Typically
cationic (co) polymers exhibit in vitro toxicity that increases with molecular weight and
cationic charge density, both of which also increase complexation and gene knockdown
ability. Utilizing lower molecular weight components, higher ordered structures can
degrade/dissociate into less toxic components. Though limited by the dynamic nature of
such associated entities, it has been reported that the use of nucleic acids as crosslinking
polyanions can result in sufficiently stable complexes.38,43,63,100,122,137
In an extension of the work by Stayton and coworkers mentioned previously,
micelles capable of complexing with siRNA in the corona while containing an endosomal
release component in the core were prepared via RAFT polymerization.38 The corona
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consisted of DMAEMA while the core block was composed of statistically incorporated
BMA, PAA, and DMAEMA (Figure 9). The hydrophobic block was synthesized to be
approximately 2.5 times larger than the hydrophilic block, and the optimum incorporation
of BMA was found to be approximately 50% in the hydrophobic block. Particle sizes of
the resulting micelles were 45 nm at pH 7.4, and upon the addition of siRNA (N:P = 4),
particle sizes remained fairly consistent at 47 nm.

Figure 9. RAFT synthesis of hydrophilic, cationic DMAEMA macroCTA and
subsequent chain extension for the preparation of an endolytic and polyampholyte block
(which incorporates DMAEMA, PAA, and BMA).39

Membrane destabilizing ability was investigated using a red blood cell hemolysis
assay. Three pH conditions were chosen to mimic cellular internalization: pH = 7.4
(extracellular), pH = 6.6 (early endosome), and pH 5.8 (late endosome). No significant
hemolytic activity was observed at pH 7.4, while decreasing pH below 7.4 resulted in
increasing hemolytic activity. siRNA was complexed at various N:P ratios to account for
any change that might be displayed in hemolytic activity due to charge-charge
interactions, and none was observed even at high N:P ratios (N:P = 8). Additionally,
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differences in hemolytic activity between linear and assembled polymer solutions were
negligible. Gene knockdown experiments were performed in HeLa cells with varying
polymer (above and below the critical micelle concentration) and siRNA concentrations
(12.5 nM–100 nM). The greatest knockdown was observed with micelles at the highest
siRNA concentrations, <90%. Investigation of uptake using FAM-labeled (6carboxyfluorescein) siRNA revealed that almost 100% of cells were transfected by
micelles, compared to only 25% in the previous study with the linear polymer system.38
Monteiro and coworkers141,142 prepared micellular nanocarriers which would selfcatalyze their own degradation. Utilizing aRAFT, poly[DMAEMA65-block-(ImPAA45co-BA29)] copolymers (Figure 10) were prepared that served two functions: endosomal
escape and “timed” siRNA release. The first block contains DMAEMA, which selfcatalyzes hydrolysis, forming poly(acrylic acid), and this block was tuned to promote
siRNA release over the course of 48 h. The release of siRNA is maximized via the
“charge-shifting” approach; which takes advantage of charge repulsion between ionized
poly(acrylic acid) and the anionic phosphodiester backbone of siRNA. The second block
promotes endosomal fusion and subsequent escape. The ImPAA and BA moieties behave
similarly to the influenza virus, promoting endosomal escape via membrane disruption.
The siRNA delivered targeted PLK1, a kinase that maintains tumorgenic phenotypes of
osteosarcoma cells, and utilizing these block copolymers, upwards of 98 % cell death was
reported. Furthermore, owing to the degradability of DMAEMA, these polymeric carriers
exhibited negligible toxicity, even at polymer concentrations > 300 μg/mL.
Seeking to utilize the advantageous degradability of DMAEAMA, these
coworkers, prepared polymeric carriers with a star architecture.143 These star systems
were prepared via chain extension of a DMAEMA macroCTA with a statistical
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incorporation of bis-N,N-(acryloyl) cysteine and DMAEMA. These systems were shown
to be nontoxic and biodegradable under physiological conditions. siRNA was delivered to
two different cell lines: pancreatic cells (MiaPaCa-2-Luc2) and lung cancer cells *H460
NSCLC). Approximately 80% reduction in mRNA and protein levels were observed in
the lung cancer cell line; however, delivery to pancreatic cells was less efficient with
~50% and ~60% reduction in mRNA and protein levels, respectively. Furthermore, these
star systems demonstrated mild success in vivo with a 60% reduction in mRNA levels in
mice exhibiting lung cancer (H460).

Figure 10. Preparation of poly[DMAEMA-b-(ImpAA-co-BA)] copolymers. These
constructs contain a self-catalyzing mechanism that promotes siRNA release and an
endosomolytic block.143

The use of higher ordered structures such as micelles and vesicles also present the
additional option of incorporating multiple therapeutic agents. Micelles with
hydrophobic cores can accommodate poorly-soluble drug payloads, while vesicles with
hydrophilic cores can accommodate water-soluble drugs. Taking advantage of this
option, Park and coworkers prepared biodegradable cationic micelles for co-delivery of
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siRNA and paclitaxel.44 ε-Caprolactone was polymerized (7 kDa, PDI = 1.26) and
subsequently N,N'-dicyclohexylcarbodiimide (DCC)-coupled to 4-cyanopentanoic acid
dithionaphthalenoate (CPADN) to prepare a macroCTA for RAFT polymerization of
DMAEMA (Figure 11). Molecular weights ranged from 9.1 kDa to 21.1 kDa with PDIs
ranging from 1.15–1.42. Micelles were prepared by direct dissolution into HAc-NaAc
buffer (pH = 5.0) overnight and had CMC values of 15.8–24.0 mg/L. Particle sizes
ranged from 54 nm to 132 nm, and possessed moderately positive surface charges (+29.3
mV to +35.5 mV). Complexation with siRNA was investigated using a gel retardation
assay, and complete retardation was observed at N:P> 4:1. siRNA transfection was
monitored in MDA-MB-435-GFP cells. The experiments were carried out utilizing N:P
= 36:1 and N:P = 12:1 for the micelles, with PEI (poly(ethylene imine)) (25 kDa) and
DMAEMA homopolymers utilized as positive controls. The micelles had much higher
transfection ability as compared to the positive controls. Cytotoxicity of the micelles was
investigated in PC3 cells. The micelles were loaded with paclitaxel (6.8 wt%), and
possessed a higher drug efficacy than free paclitaxel which the author attributed to
enhanced endocytosis of the micelles. Cells incubated with the free drug had viabilities
of around 70%, whereas cells incubated with drug-loaded micelles had viabilities of
approximately 50%, independent of the micelle concentration used. Co-delivery was
investigated in PC3 cells with paclitaxel-loaded micelles complexed with siRNA at N:P =
24. Co-delivery resulted in 90% down-regulation of VEGF (vascular endothelial growth
factor) expression whereas branched PEI exhibited 75% down-regulation. Interestingly,
co-delivery of the therapeutic agents was slightly more efficient (90% vs. 80%) than
micelle delivery of siRNA alone.
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Figure 11. Synthetic pathway for the preparation of Poly(DMAEMA-block-CL-blockDMAEMA) degradable copolymers.44

Stayton and coworkers have also developed a multitherapeutic micellar system
consisting of doxorubicin, an anthracycline utilized in many cancers, and siRNA against
plk1, which has been shown to cause cell-cycle arrest and apoptosis in cancer cell lines as
well as increased sensitivity to chemotherapeutics.63 The complexes they report consist
of three basic components: (1) cationic micelles composed of P(DMAEMA-b-BMA)
diblock copolymers (pDbB), (2) siRNA, and (3) anionic, pH-sensitive poly(styrene-altmaleic anhydride) (pSMA) polymers that mediate endosomal escape (Figure 12). pDbB
was synthesized via RAFT using dodecyl cyanovalerictrithiocarbonate (DCT) CTA and
2,2’-azobis(2-methylpropionitrile) (AIBN) radical source. The overall Mw of the
copolymer was 9.4 kDa with a PDI of 1.2. The pSMA was also synthesized via RAFT
using 4-cyanopentanoic acid dithiobenzoate (CTP) and AIBN. A Mw of 48.5 kDa was
targeted based on endolytic activity from previous studies.144

25

Figure 12. Ternary complex formation: siRNA (red), Poly(BMA) (black), Poly(D-blockB) (purple), and Poly(SMA) (blue).63

pDbB can form micelles at pH 7.4 such that the protonated DMAEMA block acts
as the corona and the hydrophobic BMA block serves as the hydrophobic core. These
micelles are positively charged with mean diameters of 37 nm. Both anionic siRNA and
pSMA can be used to complex with the positively charged DMAEMA corona.
Depending on the ratio of the three components, micelles with diameters varying from
30–100 nm can be obtained, all maintaining a solution- stable, slightly positively charged
complex (zeta potentials ranging from 0–1.2 mV). Micelles could be co-loaded with
doxorubicin up to 10 wt% with a slight increase in micelle size. The gene knockdown
ability and cell viability towards doxorubicin were investigated in both drug-sensitive
OVCAR8 and multidrug-resistant NCI/ADR-REDS ovarian cancer cell lines. The
ternary micelle complexes were able to achieve ~50% knockdown (with or without
doxorubicin) and effectively sensitized drug-resistant cells to doxorubicin resulting in a
decrease in cell viability comparable to drug-sensitive cells.
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Polymer-Inorganic Hybrid Carriers—Theranostics
Clearly the advent of controlled radical polymerization techniques has led to the
dramatic increase in use of polymers for the construction of gene delivery vehicles. Still,
many other materials have also found use in this burgeoning area. Calcium phosphate,145
silica nanoparticles,146–148 and carbon nanotubes149–152 are just a small sampling of the
many inorganic substrates that have been used in recent years as transfection agents.153,154
Indeed, the use of inorganic nanoparticles has proliferated due to their ease of synthesis,
wide range of sizes, and biocompatibility.155–158 However, the application of simple
inorganic nanoparticle constructs has been hindered due to their instability/aggregation,
low loading efficiencies, and lack of functional “handles” for targeting group
incorporation.158
Initially, the placement of polymers onto metal nanoparticles was attempted to
address issues of stability and the incorporation of reactive functionality.159,160 These
early designs utilized ill-defined polymers, most of which were adsorbed onto the metal
surface. However, developments in controlled syntheses of polymers as well as inorganic
nanoparticles have led to the construction of well-defined hybrid materials. It has been
through the combination of these materials that the development of “theranostics,” the
incorporation of therapeutic and diagnostic agents on the same platform, has occurred.161–
166

Thus, the combination of inorganic nanoparticles with organic polymers presents a

class of novel delivery vehicles with enormous potential applications.
With recent advances in the synthesis of well-defined, narrowly dispersed iron
oxide nanoparticles (IONPs), use of this material as both diagnostic agent167 and a
hyperthermia therapeutic has garnered increased attention.168 IONPs have also been used
in the delivery of oligonucleotides via interpolyelectrolyte complexation with ill-defined
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cationic polymers, such as PEI, adsorbed to their surface.29 However, their usefulness in
vitro/in vivo has been limited due to instability, aggregation, and fouling of the
nanoparticle surface. Boyer and Davis have been able to combat this problem by
developing a “grafting to” process utilizing polymers synthesized via RAFT containing a
phosphonic acid end group that has a very high affinity for iron169 (Figure 13). The
phosphonic acid is coupled to a CTA utilized in the preparation of the polymers and ends
up as a telechelic group on the terminus of the polymer chain.170 In their most recent
work, Boyer et al.170 have shown that by “co”-grafting two homopolymers, a cationic
PDMAEA (Poly(2-(N,N-dimethylamino)-ethyl acrylate)) and a hydrophilic POEGA
(poly(oligo(ethylene glycol) acrylate)) onto the surface of pre-formed IONPs. The
grafting density (0.12 chains/nm2) can be greatly increased over grafting homopolymer
(PDMAEA 0.07 chains/nm2) or even a diblock copolymer (0.06 chains/nm2) alone. This
increased grafting density has direct correlation to the overall stability of the NPs, making
them storable for months instead of days, and highly resistant to protein absorption.
Proton transverse relaxivity rates of bare NPs were compared to polymer grafted NPs and
showed no marked effect. The gene knockdown of eGFP (green fluorescent protein) in
human neuroblastoma cells of these constructs was investigated using flow cytometry.
Compared to the lipofectamine control (40%), the fluorescence intensity of cells
incubated with the co-graft IONPs was 78%, which was attributed to decreased uptake
due to pegylation of the particles. Interestingly, application of a magnetic field, which
has been shown to effect the uptake of magnetic nanoparticles in cells,171 had a dramatic
effect on the transfection efficiency, decreasing the fluorescence intensity to 50%, only
slightly higher than the lipofectamine control.
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Figure 13. A graphical representation demonstrating (A) simultaneous grafting of two
homopolymers, and (B) grafting of diblock copolymers.157

Perhaps the most successful and widely used inorganic platform is gold.
Inherently non-toxic and inert, gold nanoparticles (GNPs) are easily synthesized in a
range of sizes, easily functionalizable, and readily taken up by most cell lines.172–182 Gold
nanoparticles have also recently been approved by the FDA as formulated in the X-ray
contrast agent, AuroVist™, and have the added benefit of functioning as a diagnostic
agent.183,184 While the functionalization of gold nanoparticles with polymers has been
widely demonstrated to increase therapeutic loading,185 incorporate targeting,186–188 and
increase circulation time and stability in vivo,189 the construction of these platforms has
been limited by low polymer grafting density due to inefficient ligand exchange.
McCormick and coworkers have recently reported the synthesis of polymer-decorated
gold nanoparticles that are formed in situ by the reduction of gold aurate by amine-
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containing blocks on their RAFT polymers.40,134,190,191 In particular, P(HPMA-bDMAPMA) synthesized via aqueous RAFT was used to form and stabilize siRNA
polyplexes (Figure 14).40 The size and dispersity of these particles prior to IPEC
formation with siRNA can be controlled by varying conditions including substrate
concentration, amine to gold ratios, polymer block lengths, and reaction temperature.
The grafting densities of the polymer-stabilized GNPs was quite high, 2.7 chains/nm2, as
compared to similar systems, likely due to the extended conformation adopted by the
polymer chains on the gold surface which also leads to larger diameter particles (29 nm)
than predicted for random-coils (14 nm). The sizes of the GNPs before siRNA
complexation were determined by TEM to be ~ 6.5 nm. It should be noted that for the
complexes shown in Figure 14, the siRNA is protected against degradation by nucleases
through both steric shielding conferred by the HPMA shell and by interpolyelectrolyte
complexation with the protonated segments of the polymer vector. Luciferase expression
was used to determine transfection efficiency of these constructs in KB cell lines. In
these studies, polymer-stabilized GNPs demonstrated identical knockdown (50%) as the
commercial agent Dharmafect.
SiRNA-Polymer Conjugates
Most research on siRNA delivery has focused on the formation of
interpolyelectrolyte complexes with cationic polymers. However, many questions still
remain concerning the binding strength of these complexes, the mechanism of siRNA
release, and how these parameters affect gene knockdown
efficiency.8,10,16,19,21,23,25,26,28,29,122 A number of barriers to delivery might be overcome by
designing better therapeutic carriers utilizing modular concepts introduced by the original
Ringsdorf model, for example utilizing cleavable functionality to release siRNA.
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Figure 14. Reduction of Au
in the presence of Poly(HPMA-block-DMAPMA)
copolymers to form hydrophilic-block-cationic AuNPs and subsequent complexation of
siRNA.40

Much effort in the conjugation of biomolecules to RAFT polymers has focused on
modification of the chain ends via functionality incorporated from the R or Z groups of
the CTA agent (Figure 6).53,66,71,192–200 However, to be applicable to the delivery of
siRNA,the conjugation used must be reversible/cleavable. Bulmus and Maynard have
several examples of reversible conjugation to the terminus of polymers via a disulfide
linkage.44,192,193,196,200,201 Perhaps the most promising for delivery was conjugation of
siRNA to a water-soluble poly(ethylene glycol)-containing acrylate utilizing elegant
RAFT chemistry. 196 Simple conjugation of poly(ethylene glycol) (PEG) to siRNA via a
disulfide bond has been shown to both increase the circulation time and protect against
premature degradation.202–204 Pyridyl disulfide propanol was coupled to the CTA 2-(ethyl
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trithiocarbonate)propionic acid and used to polymerize poly(ethylene glycol) acrylate
(PEGA) (Figure 15). Linear kinetic plots were obtained in DMF at 60 oC with AIBN as
an initiator after a 20 m inhibition period. Conversions up to 80% with PDIs approaching
1.2 were obtained. Retention of the end group was confirmed by 1H NMR. Thiol
exchange between the 5’-end of the siRNA and the pyridyl disulfide was accomplished
with 88% yield. Complete cleavage of siRNA could be achieved under reductive
conditions with dithiothreitol (DTT).

Figure 15. Synthesis of a pyridyl disulfide functionalized CTA and subsequent RAFT
polymerization of PEGA.179

This thiol exchange strategy, developed by Bulmus and coworkers initially for
protein conjugation to RAFT polymers,193 was also utilized by York et al. for
conjugation of siRNA to RAFT polymers at multiple sites along the backbone.70 Instead
of conjugating one siRNA per polymer, they were able to incorporate multiple siRNAs to
increase the therapeutic payload and potentially increase the efficiency (Figure 16).
HPMA was copolymerized with APMA using V-501 (4,4’-azobis(4-cyanovaleric acid))
as the initiator and CTP as the CTA. The final polymer was end-capped with AIBN due
to the potential toxicity of the CTA end group.205 N-succinimidyl 3-(2-pyridyldithio)
propionate (SPDP) was used to functionalize the free amines of the APMA. Thiol
exchange with the sense strand of the siRNA was accomplished with 89% efficiency.
Folic acid was then conjugated to the remaining free amines for targeting. The anti-sense
strand was subsequently complexed to the polymer conjugate. Release of siRNA from
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the polymer was demonstrated under intercellular conditions with 5 mM glutathione.
About 60% of the siRNA was released in a 4 h period.

Figure 16. Reaction pathway for the synthesis of both RNA and folate conjugated
copolymers and subsequent hybridization with RNA antisense strands.70

This chapter has focused on utilizing RAFT polymerization to prepare constructs
for drug/gene delivery applications. In principle, these carriers were rationally designed
to overcome hurdles in achieving efficient delivery of siRNA. While these systems
succeeded in their stated objectives, the focus was on developing “novel” polymeric
carriers and not elucidating underlying structure-behavioral relationships governing
efficient and efficacious delivery. This dissertation seeks to elucidate such underlying
structure-property relationships, providing further insight in the rational design of
polymeric drug/gene delivery carriers.
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CHAPTER II
OBJECTIVES OF RESEARCH
While ideas for efficacious drug/gene delivery have been in circulation for many
years, techniques for achieving successful delivery have only recently emerged.
Specifically, reversible addition-fragmentation chain transfer (RAFT) and its aqueous
counterpart aRAFT. This polymerization method allows for facile preparation of
(co)polymers with tailorable architectures, pre-determined molecular weights, directly in
water. Serendipitously, small interfering RNA (siRNA), an anticancer biologic, was
discovered the same year as RAFT. With siRNA, virtually any gene of interest may be
removed post-transcriptionally. However, delivery of siRNA possesses several barriers:
reduced cellular uptake due to charge repulsion, lack of cellular specificity, and reduced
circulation due to rapid clearance. With these challenges in mind, several researchers (see
Chapter I) as well as the McCormick group, have developed polymeric delivery vehicles
utilizing the RAFT process which significantly enhance siRNA efficacy in vitro.
Specifically, polymeric carriers which possess endosomal escape abilities, cell targeting
functionality, and self-degradative mechanisms have been prepared. Despite these
advancements, the precise mechanisms of siRNA release and delivery to targeted cells
have yet to be elucidated. Fundamental insights into the barriers which limit drug efficacy
must be achieved before true potential can be achieved.
This dissertation seeks to ascertain structure-property relationships affecting
endosomal escape and drug release. Furthermore, this dissertation is divided into three
sections. The first section describes the synthesis of pH-responsive poly[HPMA-block(L-Glu)] copolymers as well as their ability to prompt membrane disruption; these novel,
endolytic copolymers were specifically designed to address endosomal escape. The
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second section describes the structure-property relationships involved in complex
dissociation. A series of hydrophilic-block-cationic copolymers consisting of
poly[(HPMA-stat-APMA)-block-DMAPMA) were prepared via aRAFT to elucidate a
pathway for siRNA release, and how this release profile affects gene suppression in vitro.
The last section investigates the effects on drug efficacy via modifications to
oligonucleotide secondary structure. A novel therapeutic, AS1411, a G-quadruplex
forming single-stranded DNA, was utilized since defects in secondary structure are less
tolerable for this anticancer biologic. Again, hydrophilic-block-cationic copolymers were
utilized as polymeric carriers to ascertain drug efficacy in vitro.
The specific objectives of this research are the following:
1.

Prepare well-defined macroCTAs comprised of HPMA and APMA.

2.

Prepare well-defined hydrophilic-block-cationic copolymers via chain
extensions of macroCTA with DMAPMA.

3.

Modify HPMA macroCTA via thiol-ene Michael addition for the conversion
into a macroinitiator.

4.

Prepare pH-responsive, endolytic block copolymers consisting of HPMA and
γ-benzyl glutamic acid utilizing HPMA macroinitiator.

5.

Characterize all (co)polymers, macroCTAs, and macroinitiators with respect
to Mw, Mn, PDI, and molar composition utilizing ASEC-MALLS and 1H
NMR.

6.

Determine coil-to-helix transitions of poly[HPMA-block-(L-Glu)] copolymers
utilizing a pH-stimulus via circular dichroism.

35
7.

Determine structure-property relationships of poly[HPMA-block-(L-Glu)]
copolymers which promote hemolysis and dye leakage from artificial
membranes under conditions mimicking the endosome.

8.

Prepare charge neutral block ionomer complexes comprised of an
oligonucleotide and poly[(HPMA-stat-APMA)-block-DMAPM hydrophilicblock-cationic copolymers.

9.

Characterize block ionomer complexes with respect to size, charge, and
structure utilizing dynamic light scattering, ζ-potential, gel electrophoresis,
and circular dichroism.

10.

Determine structure-property relationships governing binding strength,
stoichiometry, electrostatic complex dissociation, and gene suppression
utilizing solution differential scanning calorimetry, analytical
ultracentrifugation, and relative luminescence.

11.

Ascertain the effects of secondary structure modification of G-quadruplexes
on drug efficacy delivered by poly[(HPMA-stat-APMA)-block-DMAPMA
copolymers utilizing circular dichroism, dynamic light scattering, ζ-potential,
gel electrophoresis, and cell viability.
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CHAPTER III
EXPERIMENTAL
Materials
All reagents were purchased from Sigma and used without further purification
unless otherwise noted. N-(3-aminopropyl)methacrylamide (APMA) was purchased from
Polysciences. 4,4’-Azobiscyanovaleric acid (V-501) (Wako) and azobisisobutryonitrile
(AIBN) were recrystallized twice from methanol. 4-cyano-4[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP),39 4-cyano pentanoic acid
dithiobenzoate (CTP),206 di-N-hydroxy succinimide activated folic acid (diNHS-FA),42
and N-(2-hydroxypropyl)methacrylamide (HPMA)207 were prepared as previously
reported. N,N-(3-dimethylamiopropyl)methacrylamide (DMAPMA) and triethylamine
(TEA) were distilled prior to use. HPLC purified oligonucleotides (siRNA against
Gaussia Luciferase and the dsDNA analogue of siRNA) were purchased from Integrated
DNA Technologies, Inc. The siRNA sequences targeting Guassia Luciferase are as
follows: Sense strand 5’-AGAUGUGCAACUUUUGCUACCGCAUCU-3’ and the
antisense strand 5’-AGGAGAUGCGGUAGCAAAAGUUGCACAUCUUU-3’. The
DNA analogue sequences of siRNA are as follows: Sense strand 5’AGATGTGCAATTTTGCTACCGCATCT-3’ and the antisense strand 5’AGGAGATGCGGTAGCAAAAGTTGCACATCTTT-3’. Oligonucelotides (siRNA and
dsDNA) were heated at 95 °C for 10 min and were allowed to slowly cool to room
temperature prior to use. Concentrations of oligonucleotide (siRNA and dsDNA) are
reported as duplex concentrations unless otherwise noted. The Biolux® Gaussia
Luciferase assay kit used for the determination of gene suppression was purchased from
New England Biolabs, Inc. Gibco® RPMI 1640 cell culture media (with and without folic
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acid) were purchased from Life Technologies Corporation. KB cells (human epidermal
cancer cells) expressing the Gaussia Luciferase gene (KB-GLuc) were prepared as
previously reported. For reactions requiring nitrogen, ultrahigh purity nitrogen (purity ≥
99.998%) was used. Spectra/Por® regenerated cellulose dialysis membranes (Spectrum
Laboratories, Inc) with a molecular weight cut-off of 12–14 kDa were used for dialysis.
Polymer Synthesis
Synthesis of γ-Benzyl-L-Glutamate-NCA
γ-Benzyl-L-glutamate (10 g, 42.1 mmol) was added to a flame-dried reaction
flask equipped with a stir bar and placed onto a Schlenk line; the flask was evacuated
under reduced pressure followed by the introduction of nitrogen. Approximately 100 mL
of THF was added to yield a final concentration of ~0.1 g/mL, and the slurry was stirred
under nitrogen for 20 min at 75 oC. Triphosgene (6 g, 20.2 mmol) dissolved in 10 mL of
THF was added to the mixture under a nitrogen atmosphere, and a drying tube was
attached to the reaction flask. The reaction was allowed to proceed for ~ 1 h, as THF
slowly evaporated to give a final volume of ~ 20–30 mL. After cooling, the mixture was
precipitated into hexanes. The recovered precipitate was then re-dissolved in THF; 2–3 g
of decolorizing charcoal was then added and the mixture was allowed to stir overnight to
remove residual hydrochloric acid. The mixture was then passed through a Celite column
to remove charcoal and re-precipitated into hexanes and cooled overnight. The resulting
white powder was collected and dried under vacuum overnight to produce γ-Benzyl-Lglutamate-NCA, with standard yields between 75 and 85 %: 1H NMR (DMSO-d6) δ
9.15–9.05 (Ring, COOH-NH, s), 7.40–7.25 (Ar, s), 5.15–5.05 (Ring, COOH-CH-CH2, t)
2.60–2.40 (COOH-CH2, d) 2.2–1.80 (COOH-CH2-CH2, m).
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Figure 17. Structures of poly(HPMA) (P1) and poly(HPMA)-NH2 macroinitiator (P2).
MacroCTA of poly(HPMA) (P1)
A poly(HPMA) macroCTA (P1) was prepared employing V-501 as the primary
radical source and CEP as the chain transfer agent at 70 °C. To a 50 mL round-bottomed
flask HPMA (2.86 g, 0.02 mol) dissolved in acetate buffer (pH 5.2, 0.27 M acetic acid
and 0.73 M sodium acetate) was added and diluted to a final volume of 20 mL ([M]o = 1
M). The round-bottomed flask was septum-sealed and purged with nitrogen for 1 h prior
to polymerization. The macroCTA was reacted at a [M]o/[CTA] ratio = 400/1, while the
[CTA]/[I] ratio was kept at 5/1, and the polymerization was allowed to proceed for 3.5 h
before being quenched with liquid nitrogen followed by exposure to air. P1 was isolated
by dialysis (pH 3–4) at 4 °C and recovered by lyophilization yielding 1.6 g (93%).
Poly(HPMA) End-Capping with APMA (P2)
P1 was converted into a macroinitiator (P2) via simultaneous aminolysis and
thiol-ene Michael addition with APMA. The reaction is as follows. P1 (305 mg, 9.5
μmol) was combined with APMA (170 mg, 0.95 mmol) in a septum sealed scintillation
vial equipped with a stir bar, then dissolved in 5 mL of DI H2O, and the pH elevated to 10
with 0.1 M NaOH. The reaction temperature was maintained at 70 °C for 48 h. P2 was
isolated by dialysis in DI H2O for 48 h and recovered by lyophilization yielding 300 mg
(98%).
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Figure 18. Structures of poly[HPMA-block-(γ-benzyl-L-glutamate)] (P3–P5) and
poly[HPMA-block-(L-Glu)] (P6–P8) block copolymers.
Poly(HPMA) Chain-Extension with γ-Benzyl-L-Glutamate-NCA (P3–P5)
Poly(HPMA)-NH2 (P2) was used to initiate ring opening polymerization (ROP) of
the γ-Benzyl-L-glutamate-NCA, thereby yielding polypHPMA-block-(benzyl-Lglutamate)] block copolymers. A typical reaction is as follows. In a 25 mL roundbottomed flask, P2 (50 mg, 1.56 μmol) was dissolved in 5 mL of dry DMF. γ-Benzyl-Lglutamate-NCA (10.3 mg, 38.9 μmol) was also dissolved in 5 mL of dry DMF and was
immediately added via a glass, gas-tight syringe to the macroinitiator solution. Reactions
were carried out for 5 days at 0 °C under a nitrogen atmosphere.208 The polymer was
precipitated into ether, re-dissolved in chloroform, and re-precipitated into ether to
eliminate unreacted NCA.
Deprotection of Poly[HPMA-block-( γ -Benzyl-L-Glutamate)]Block Copolymers (P6–P8)
Benzyl protecting groups were removed by hydrolysis in a 50:50 mixture of
trifluoroacetic acid (TFA) and hydrobromic acid (HBr)208 at room temperature, followed
by dialysis and lyophilizaton to yield pH-responsive P6–P8 block copolymers. Recovered
yields were ~ 95 %.
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Synthesis of poly(HPMA-stat-APMA) macroCTA (P9)
A poly(HPMA-stat-APMA) macroCTA (P9) (CTA) was prepared employing V501 as the primary radical source and CTP as the chain transfer agent at 70 °C. HPMA
(6.80 g, 47.5 mmol) and APMA (405 mg, 2.28 mmol) were added to a 100 mL roundbottomed flask, dissolved in 1 M acetate buffer (pH 5.2, 0.27 M acetic acid and 0.73 M
sodium acetate), and diluted to a final volume of 50 mL ([M]o = 1M). The initial feed
composition was 95 mol % HPMA and 5 mol % APMA. The round-bottomed flask was
septum-sealed and purged with nitrogen for 1 h prior to polymerization. The HPMA-statAPMA macroCTA was prepared with a [M]o/[CTA] ratio = 800/1, while the [CTA]/[I]
ratio was kept at 5/1; the reaction was allowed to proceed for 3.5 h. The polymerization
was quenched by rapid cooling in liquid nitrogen followed by exposure to air. P9 was
isolated by dialysis (pH 3–4) at 4 °C and recovered by lyophilization with a yield of 93%.

Figure 19. Structures of poly(HPMA-stat-APMA) macroCTA (P9) and poly[(HPMAstat-APMA)-block-DMAPMA] (P10–P12) block copolymers.

Synthesis of poly[(HPMA-stat-APMA)-block-DMAPMA] copolymers (P10–P12)
P9 was chain extended with DMAPMA also using V-501 as the radical source at
70 °C. DMAPMA and P9 were added to a round-bottomed flask, dissolved in acetate
buffer to give [M]o = 1M. The round-bottomed flask was septum-sealed and
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subsequently purged with nitrogen for 1 h. Block copolymers were prepared with a
[M]o/[CTA] = 200, while the [CTA]/[I] was kept at 5/1. Each polymerization was
terminated at predetermined time intervals by rapid cooling in liquid nitrogen and
subsequent exposure to air. The poly[(HPMA-stat-APMA)-block-DMAPMA]
copolymers were purified by dialysis (pH 3–4, 4°C) and recovered by lyophilization with
yields of 92–97%.
Thiocarbonylthio moieties from poly[(HPMA-stat-APMA)-block-DMAPMA]
copolymers were removed following a standard literature procedure.209 A typical reaction
is as follows: P10 (500 mg,11.8 μmol) was added to a 25 mL round-bottomed flask and
dissolved with 6.0 mL of DMF. Azobisisobutyronitrile (AIBN; 49.1 mg, 0.300 mmol)
was then added to the flask giving an AIBN/copolymer ratio of 25:1. The following
solution was then septum-sealed and purged with nitrogen for 1 h and allowed to react at
70 °C for 4 h. The resulting copolymer was precipitated from DMF in cold, anhydrous
diethyl ether and washed repeatedly. This step was repeated three times, and the
copolymer was dried in vacuo overnight. The recovered yields were 85–89%.

Figure 20. Structures of poly(HPMA-stat-APMA) macroCTA (P13) and poly[(HPMAstat-APMA)-block-DMAPMA] (P14–P16) block copolymers.
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Copolymer functionalization with folic acid
DiNHS-FA was prepared following a standard literature procedure.42 Following
isolation of the chain terminated block copolymer, the pendent, functional, primary amine
groups from the incorporated APMA were labeled with NHS-activated folic acid. A
typical reaction is as follows: 50 mg (1.18 μmol) of P10 copolymer was dissolved in 390
μL of DMSO to give a final concentration of 3.00 mM. A total of 150 times excess of
diNHS-FA (116 mg) was then dissolved in 350 μL of DMSO, and the P10 copolymer
solution was added to the diNHS-FA solution at a rate of 20 μL every 20 min.
Triethylamine (TEA) was added to a final concentration of 39 mM to serve as a catalyst.
The resulting solution was shielded from light and allowed to react for 48 h at room
temperature. Following reaction, excess ammonium hydroxide (100% by volume) was
added to quench the remaining activated esters from activated folic acid. Quenching was
carried out for 24 h. The resulting reaction mixture was then directly placed in dialysis
tubing and was first dialyzed against 0.6 M NaCl solution for 24 h followed by dialysis
against DI water for 3 days. The folate-conjugated P10–P12 copolymers were recovered
by lyophilization with yields of 96–98%.
Formation of Hydrophilic-block-Cationic/Oligonucleotide Complexes
Preparation of copolymer/GLuc DNA complexes for solution differential scanning
calorimetry
Folic acid labeled hydrophilic-block-cationic copolymers (P10–P12)/GLuc DNA
complexes were prepared with a N:P ratio = 1 (i.e., neutral complexes). The GLuc DNA
duplex concentration was maintained at 75 μM for all complexes. A typical preparation is
as follows: 128 μL of a 600 μM GLuc DNA stock solution was combined with 417.7 μL
of sodium cacadylate buffer (10 mM NaAs). Next, 454.3 μL of a 370.4 μM P10 stock
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solution was added. The GLuc DNA/copolymer complex solution was vortexed and
equilibrated for 30 min. After equilibration, the solution was degassed for 30 min prior to
DSC measurements. The DNA and polymer stock solutions were prepared in 10 mM
sodium cacadylate buffer at pH 7.2.
Preparation of copolymer/siRNA complexes for gene suppression
Folic acid labeled hydrophilic-block-cationic copolymers (P10–P12) /siRNA
complexes were prepared with a N:P ratio = 1; the siRNA concentration was maintained
at 100 nM. A typical preparation is as follows: 1.298 μL of a 185.2 μM P10 solution was
combined with 3.3 μL of a 20 μM siRNA stock solution. This copolymer/siRNA complex
solution was then diluted with 127.4 μL of RPMI 1640 medium containing no FBS. The
solution was mixed by vortexing and equilibrated for 30 min. After equilibrating, the
solution was further diluted with 528 μL of RPMI 1640 medium (supplemented with
FBS) and vortexed to ensure a homogenous solution. The RNA and polymer stock
solutions were prepared in 10 mM phosphate buffer at pH 7.4.
Fluorescein-POPC (fPOPC) Liposome Preparation and Dye Release Studies
The preparation of dye loaded POPC liposomes followed a standard literature
procedure.210 In a 25 mL round-bottomed flask, 5 mg of POPC was dissolved in 10 mL of
chloroform. Then the chloroform was removed by rotary evaporation, and subsequently,
the flask was placed under a high vac for 8 h. The resulting film was hydrated with PBS
at the appropriate pH containing fluorescein (40 mM). The film was subjected to five
freeze-pump-thaw cycles, and subsequently extruded (20 passes) through two stacked
200 nm pore PC membranes at 40 °C. Finally, free fluorescein was removed via a
Sephadex-25 column eluted with PBS (20 mM Pi, 150 mM NaCl) at the appropriate pH.
The resulting fPOPC liposomes possessed hydrodynamic radii of 90 nm with PDIs < 0.2.
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P6–P8 Block copolymers (200 μg/mL) were incubated with fPOPC at the appropriate pH
for 1 h at room temperature. The mixture was then vortexed, and the fluorescence
intensities measured using a PTI spectrofluorometer. Measurements were acquired with a
460 nm excitation (isobestic point) and 520 nm emission. The slit widths were adjusted
for each pH and ranged from 0.5 mm–0.3 mm (pHs 4.0–7.4). All fluorescein dye release
experiments were performed in triplicate with Triton-X100 (0.1 wt%) utilized as the
positive control, and the percent release was determined using equation 1, in which F(T)
is the fluorescence observed when incubated with Triton-X100, F(P) is the fluorescence
observed when incubated with P6–P8 copolymers, and F(C) is the fluorescence observed
with nothing added to the prepared POPC lipids.
% Release = [F(T) - F(P)]/[F(T)-F(C)] * 100 (eq 1)
Red Blood Cell Hemolysis Assay
Bovine Blood was drawn into vacutainers containing EDTA. The blood was
centrifuged, plasma decanted, and washed with 150 mM NaCl (three times). Finally, the
red blood cells (RBC) were resuspended in PBS (10 mM Pi, 150 mM NaCl) at either pH
7.4 or pH 5.5 to mimic physiological and endosomal pHs, respectively. Varying
concentrations (10 μg/mL–400 μg/mL) of P6–P8 copolymers (100 μL) were incubated
with 100 μL of RBC for 1 h at 37 °C. After incubation, the solution was centrifuged, and
the supernatant was monitored at 541 nm for the presence of hemoglobin. All hemolysis
experiments were performed in triplicate. Triton-X100 (0.1 wt%) was utilized as the
positive control, and the percent release was determined using equation 2, in which A(T)
is the absorbance observed when the liposomes are incubated with Triton-X100, A(P) is
the absorbance observed when incubated with P6–P8 copolymers, and A(C) is the
absorbance observed with nothing added to the red blood cells.
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(eq 2)

Gene Suppression of Gaussia Luciferase in KB Cells
Cell culture
KB-GLuc cells were maintained and proliferated in RPMI 1640 (with folic acid)
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and
100 μg/mL streptomycin at 37 °C in 95% air humidified atmosphere and 5% CO2.
Gene suppression
Twenty four hours prior to treatment, the KB-GLuc cell medium was replaced
with RPMI 1640 medium containing no folic acid and was supplemented with 10% FBS.
Then the cells (12,000 cells per well) were seeded in a 48 well plate (Corning Inc.). Cells
were treated with 200 μL of a hydrophilic-block-cationic copolymer (P10–P12)/siRNA
complex solution. Dharmafect was utilized as the positive control, and the preparation of
Dharmafect/siRNA complexes followed the manufacturer protocols. The delivered
siRNA concentration was maintained at 100 nM for all complexes, and the KB-GLuc
cells were treated for 24–48 h prior to measurement. The extent of Gaussia Luciferase
suppression was determined using a Biolux® Gaussia Luciferase assay kit (New England
Biolabs, Inc.). After incubation, 10 μL of medium was transferred to a 96 well plate and
combined with 10 μL of assay buffer. The luminescence was immediately determined
utilizing a Biotek Synergy2 MultiMode Microplate Reader. All gene suppression studies
were performed in triplicate. The passage number for KB-GLuc cells was 11.
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Characterization
Determination of (Co)Polymer Molecular Weight via Aqueous Size Exclusion
Chromatography
Poly(HPMA) (P1), Poly(HPMA)-NH2 (P2), and Poly[HPMA-block-(L-Glu)]s
(P6–P8) were characterized by aqueous size exclusion chromatography (ASEC) using an
eluent of 20 wt% acetonitrile/0.05 M Na2SO4 (aq) at a flow rate of 0.300 mL/min at 25
°C, TOSOH Bioscience, LLC TSKgel columns (4 and 6 μm), a Polymer Laboratories
LC1200 UV/Vis detector, a Wyatt Optilab DSP interferometric refractometer (λ = 690
nm), and a Wyatt DAWN-DSP multi-angle laser light scattering (MALLS) detector (λ =
633 nm). Absolute molecular weights and polydispersities were calculated using the
Wyatt Astra (version 4) software. The dn/dc measurements were performed with a Wyatt
Optilab DSP interferometric refractometer (λ = 690 nm) at 35 °C and determined using
Wyatt DNDC (version 5.90.03). Conversions for the P1 and the chain extension with γBenzyl-L-glutamate-NCA were determined by comparing the area of the monomeric UV
signal detected at 274 nm at t0 to the area at tx using a Polymer Laboratories LC1200
UV/vis detector.
Poly(HPMA-stat-APMA) (P9) and Poly[(HPMA-stat-APMA)-block-DMAPMA]
(P10–P12) copolymers were characterized by aqueous size exclusion chromatography
(ASEC) using an eluent of 1 wt% acetic acid/0.1 M Na2SO4 (aq) at a flow rate of 0.250
mL/min at 25 °C, Eprogen, Inc. CATSEC columns (100, 300, and 1000 Å), a Polymer
Laboratories LC1200 UV/Vis detector, a Wyatt Optilab DSP interferometric
refractometer (λ = 690 nm), and a Wyatt DAWN-DSP multi-angle laser light scattering
(MALLS) detector (λ = 633 nm). Absolute molecular weights and polydispersities were
calculated using the Wyatt Astra (version 4) software. The dn/dc measurements for P9
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and P10–P12 (co)polymers were performed with a Wyatt Optilab DSP interferometric
refractometer (λ = 690 nm) at 35 °C and determined using Wyatt DNDC (version
5.90.03). Conversions for P9 and the chain extension with DMAPMA were determined
by comparing the area of the monomeric UV signal detected at 274 nm at t0 to the area at
tx using a Polymer Laboratories LC1200 UV/vis detector.
Determination of (Co)Polymer Compositions via 1H NMR
P3–P8 block copolymer compositions before deprotection were determined with a
Varian MercuryPLUS 300 MHz spectrometer in DMSO-d6 supplemented with 15 wt %
TFA, and spectra were recorded with a delay time of 2 s. 1H NMR was used to determine
the copolymer composition of P3–P5 copolymers by integration of the relative intensities
of the methyne-proton resonances of HPMA at 3.75 ppm and the aromatic-proton
resonances of γ-benzyl L-glutamate at 7.2 ppm.
Hydrophilic-block-cationic copolymer (P10–P12) compositions were determined
with a Varian MercuryPLUS 300 MHz spectrometer in D2O, and spectra were recorded
with a delay time of 2 s. 1H NMR was used to determine the copolymer composition of
P9 and P10–P12 (co)polymers by integration of the relative intensities of the methyneproton resonances of HPMA at 3.75 ppm and the dimethyl-proton resonances of
DMAPMA at 2.75 ppm.
Conjugation of folic acid to P10–P12 copolymers was verified by 1H NMR and
UV/vis spectroscopy. 1H NMR was performed on a Varian MercuryPLUS 300 MHz
spectrometer in DMSO-d6 with delay times of 2s. The amount of conjugated folic acid
was estimated by integration of the methyne-proton resonance of HPMA at 3.75 ppm and
the proton resonance of folic acid at 8.64 ppm (s, PtC7H, 1H). These values were
estimated by employing a Lorentzian/Guassian line fit using MestReNova (version 6.0.2-
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5475). UV/vis spectroscopy was carried out using a PerkinElmer Lambda 35
spectrophotometer for folic acid conjugated P10–P12 copolymers. An average extinction
coefficient of 8000 M-1cm-1 for free folic acid in phosphate buffer (10 mM Pi, 100mM
NaCl, pH 7.4) was used to determine the number of folic acid units.
Determination of Hydrodynamic Radius for (Co)Polymers and (Co)PolymerOligonucleotide complexes
Variable-angle dynamic light scattering (DLS) measurements of hydrophilicblock-cationic copolymer/siRNA complexes under aqueous conditions were performed
using incident light of 633 nm from a Spectra Physics Model 127 He-Ne laser operating
at 40 mW. The angular dependence (60°–120° in 10° increments) of the autocorrelator
functions was determined with a Brookhaven Instruments BI-200SM goniometer with an
avalanche photodiode detector and TurboCorr correlator. DLS measurements were
carried out at a complex concentration (siRNA + FA-block copolymer) of 1.0 mg/mL in
phosphate buffer (10 mM Pi, pH 7.4) at 25 °C. The mutual diffusion coefficients (Dm)
were determined from the relation

in which Γ and q2 represent the decay rate of the autocorrelation function and the square
of the scalar magnitude of the scattering vector, respectively. The hydrodynamic radius
(Rh) was then calculated from the Stokes-Einstein equation

in which η is the solution viscosity, kb is Boltzman’s constant, and T is the temperature in
Kelvin. Zeta-potential measurements were carried out at a complex concentration of 0.5
mg/mL in 20 mM NaCl solution at pH 7.4 using a Malvern Zetasizer Nano Series
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Instrument. Samples were vortexed to ensure a homogeneous solution and equilibrated
for 30 min at 25 °C prior to measurement. To remove dust, samples were centrifuged at
14,000 RPM for 10 min. Both DLS and zeta-potential measurements were performed in
triplicate.
Circular Dichroism of poly[HPMA-b-(L-Glu)]s (P6–P8)
The ellipticity of P6–P8 copolymers was determined utilizing a Jasco J-815
circular dichroism spectropolarimeter. Samples were dissolved in DI H2O, and the pH
was adjusted with 0.1 M HCl. Final sample concentrations ranged from 0.3–0.5 mg/mL,
and solutions were allowed to equilibrate for 1 day prior to measurement. The spectra
were obtained with a scan rate of 10 nm/min, a 0.5 nm bandwidth, and a time constant of
2 s. The signal-to-noise for all spectra was doubled by averaging four scans. The
formation of α-helices was determined by monitoring the presence of the characteristic
double minima at 220 and 208 nm.211
The ellipticity of the oligonucleotides (siRNA and GLuc DNA) as well as the
P10–P12/oligonucleotide complexes was determined utilizing a Jasco J-815 circular
dichroism spectropolarimeter. Oligonucleotides were prepared in phosphate buffer (10
mM Pi, pH 7.4) at a concentration of 1.0 μM. Oligonucleotide/P10–P12 copolymer
complexes were also prepared in phosphate buffer but at a concentration of 0.5 μM.
Spectra were recorded with a scan rate of 10 nm/min, a 0.5 nm bandwidth, and a time
constant of 2 s. The signal-to-noise was doubled for all spectra by averaging four scans.
To determine defects of the secondary structure, the characteristic peaks of B-form
oligonucleotide (right-handed helices) at 280 nm (maximum), 250 nm (minimum), and
260 nm crossover (from positive to negative) were monitored for discrepancies before
and after complexation.212
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Differential Scanning Calorimetry of Hydrophilic-block-Cationic Polymers and
Hydrophilic-block-Cationic-Oligonucleotide Complexes
All calorimetric experiments were carried out using a Calorimetric Sciences
Corporation Nano DSC-II solution differential scanning calorimeter (DSC). Sodium
cacadylate buffer (10 mM, pH 7.2) was used for the running buffer. The GLuc DNA
(analogue of Gaussia Luciferase siRNA) concentration was maintained at 75 μM while
the concentrations of hydrophilic-block-cationic (P10–P12) copolymers were adjusted to
maintain a nitrogen-to-phosphate (N:P) ratio equal to 1 (i.e., neutral complexes). CpCalc
(Version 2.1, Calorimetric Sciences Corp.) was used to subtract buffer-buffer scans from
buffer-sample scans. Linear-polynomial baselines were applied to each scan for the
determination of the molar heat capacity.
Determination of Copolymer-Oligonucleotide Complex Binding Strength Utilizing
Analytical Ultracentrifugation
Sedimentation-velocity experiments were performed in a Beckman XLA
Analytical Ultracentrifuge at 20 °C at 50K rpm. Data were collected at 260 nm and
processed in DCDT+ to produce g(s) sedimentation coefficient distributions.213 A fixed
concentration of ssDNA was titrated with increasing concentrations of P10 or P11. Data
were converted to Sw and analyzed to a 1:1 binding model in Scientist 3.214
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CHAPTER IV
RESULTS AND DISCUSSION
Section I. Endolytic, pH-Responsive HPMA-b-(L-Glu) Copolymers Synthesized via
Sequential Aqueous RAFT and Ring Opening Polymerizations
Overview
Remarkable progress has been made over the last decade in the design of
polymeric vehicles in order to achieve cellular targeting,215 increased blood
circulation,216–218 drug/gene protection,219–221 reduced cytotoxicity,222–225 etc.20 Despite
these advances, a number of challenges remain for efficacious gene/drug delivery.226,227
An ideal carrier should provide protection and solubility during circulation as well as a
mechanism for targeting and entry into specified cells. Once delivered the
drug/gene/carrier complex must overcome other critical barriers including trafficking to
the lysosome, where the cargo can be degraded, or transport outside the cell into the
extracellular milieu. A promising approach for an ideal polymeric drug vehicle is
inclusion of a modular segment promoting disruption of the endosomal membrane at an
appropriate time, allowing drug/gene release into the cytoplasm.
Some polymeric carriers rely on an osmotic swelling mechanism (“proton-sponge
effect”) to escape the endosome. Alternatively, poly(amido amines), prepared by
Duncan228–230 and Wagner,231 and poly(aspartamides), prepared by Kataoka and
coworkers,232–234 exploit the enhanced buffering capacity of pendant and backbone
amines to facilitate endosomal swelling and rupture. While these systems demonstrate
improved efficacy both in vitro and in vivo, the toxicity of amines is still a concern as is
the necessity of a “charge-shielding” block such as PEG or HPMA. In order to alleviate
unwanted electrostatic effects and undesirable toxicity, Convertine et al.38,39,235 prepared
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endosomolytic block copolymers containing N,N-(2-dimethylaminoethyl)methacrylate
(DMAEMA), propylacrylic acid, and butyl methacrylate (BMA). DMAEMA served to
bind siRNA, while propylacrylic acid masked the hydrophobic BMA. At endosomal pH,
propylacrylic acid segments are protonated, thus increasing the hydrophobicity of the
block copolymer and destabilizing the endosomal membrane.
Naturally-occurring peptides and proteins provide several pathways for
endosomal disruption via hydrophobic alignment between the α-helix and bilayer surface,
usually resulting in electrostatic interactions of the membrane that promote
permeability.236 Such pH-responsive coil-to-helix transitions are attractive features of
these biopolymers that offer opportunities for synthetic mimicry. Peptides based on
melittin,237 a component of bee venoms, as well as the lytic amino-terminus of the
influenza virus HA-2238 have been conjugated to polymeric vehicles increasing pDNA
and siRNA efficacy both in vitro and in vivo. To realize a nature-inspired mimic, Ncarboxyanhydride (NCA) polymerization239–241 has been used to prepare synthetic
peptides that undergo stimuli-responsive conformational changes into α-helices, β-sheets,
and other ordered structures.242 These conformational changes are facile and reversible,
and they have been capitalized on for triggered drug release in vitro.243
In recent years our research has centered on the development of a modular
drug/siRNA delivery platform, capitalizing on the attributes afforded by aqueous RAFT
polymerization7 for synthesis of biologically relevant systems.40,41 (For example, homoand block copolymers of (3-guanidinopropyl)methacrylamide (GPMA) were shown to
serve efficiently as cell-penetrating mimics of natural peptides.244 Folate targeting groups
for receptor-mediated endocytosis have also been attached to both interpolyelectrolyte
siRNA complexes42 and amphiphilic diblock copolymers with disulfide-bound, pendant
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siRNA.245 While siRNA uptake and trafficking to the endosome occurred with both of
these charge-neutral delivery vectors, only the former showed significant gene
knockdown. We attribute negligible gene suppression to inability of the latter construct as
designed to escape the endosome. Herein, we report the controlled synthesis,
characterization, and endolytic activity of a series of HPMA-block-(L-Glu) copolymers
specifically designed to elicit membrane disruption. To our knowledge, this facile
synthetic approach using sequential RAFT polymerization and aminolysis to produce a
telechelic, amine-functional macroinitiator followed by NCA polymerization and
hydrolysis has not been previously reported. The pH-dependent coil-to-helix transitions
of the L-glutamic acid (L-Glu) block were followed by circular dichroism. Membrane
disruption was demonstrated by red blood cell hemolysis and fluorescein release from
POPC vesicles.

Scheme 1. Synthetic pathway for the preparation of P6–P8 copolymers.
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Synthesis of HPMA Homopolymer and Chain-end Functionalization
P1 was prepared via aqueous RAFT polymerization (Scheme 1) in order to yield a
water-soluble, biocompatible segment with telechelic246,247 functionality appropriate for
further modification to a macroinitiator for block copolymerization. The polymerization
was carried out in acetate buffer (pH 5.2) at 70 °C using 4-cyano-4[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP) and 4,4’-azobis(4cyanopentanoic acid) (V-501) as the CTA and initiator, respectively. P1 was end-capped
with a primary amine containing monomer N-(3-aminopropyl)methacrylamide (APMA)
via simultaneous aminolysis and thiol-ene Michael addition. To ensure quantitative thiolene coupling, the pH was elevated (>10) to deprotonate the amine, and the reaction was
allowed to proceed at elevated temperature (70 °C) for an extended period of time (48 h).
End-capping efficiency was determined via a Ninhydrin assay248 (See Appendix), and
primary amine incorporation exceeded 96%. Aqueous size exclusion chromatography
(ASEC) was used to determine PDIs, molecular weights, and macro disulfide coupling;
the ASEC chromatograms (Figure 20) are shown prior to and after chain-end
functionalization with APMA, indicating narrow distributions (PDIs <1.1).
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Figure 21. ASEC-MALLS of P1 (black) and P2 (red). P2 is offset for clarity.

Figure 22. 1H NMR of P2 and P3–P5. P2 was recorded in D2O while P3–P5 were
recorded in DMSO-d6 supplemented with TFA (15 wt%).
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Synthesis of (HPMA-b-Glu) Block Copolymers
Utilizing P2 as a macroinitiator, a series of chain extensions was accomplished
via ring opening polymerization of N-carboxyanhydride, γ-Benzyl-L-glutamte-NCA, in
DMF. By altering the [M]/[I] ratio, where [M] = γ-Benzyl-L-glutamte-NCA (benzyl
protected glutamic acid) and [I] = P(HPMA)-NH2, a range of block lengths was targeted.
In order to prevent anticipated side reactions,239,249–252 the polymerizations were
conducted at 0 °C under an atmosphere of nitrogen. Copolymer compositions for the
block copolymers were determined using 1H NMR by comparing the relative intensities
of the aromatic-protons resonances of benzyl L-glutamate units at 7.2 ppm to the
methyne-proton resonances of the HPMA repeats at 3.75 ppm. Spectra of the
poly(HPMA220)-NH2 macroinitiator (P2) and three copolymers with benzyl-L-glutamate
blocks of DP 33, 58, and 78 are shown in Figure 21. Deprotection of benzyl-L-glutamate
units was accomplished under acidic conditions at room temperature using a 50:50
mixture of TFA and HBr.208,253 Copolymer molecular weights, PDIs, compositions, and
dn/dc values are presented in Table 1. Size exclusion chromatograms (Figure 22)
indicate successful chain extension with shifts to lower elution volume as the
polymerization progressed. The copolymer molecular weights determined directly by
ASEC-MALLS correlate well with those calculated from NMR compositional data; PDI
values are narrow, ranging from 1.08–1.20. The deviations in experimental and
theoretical Mn values are relatively small and may be attributed to incomplete conversion
of the HPMA macroCTA to the amine-terminated macroinitiator upon addition of
APMA.
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Figure 23. ASEC-MALLS of P1 (black), P6(red), P7 (blue), and P8 (cyan).
α-Helix Formation
Circular dichroism211 is an exceptionally valuable technique for ascertaining
structural information of proteins,254 nucleic acids,255 and chiral self-assemblies.256 By
measuring the differences between left-handed and right-handed absorbances of chiral or
asymmetric species, insight into the secondary structure can be gained. The utility of the
P6–P8 copolymers according to our synthetic design lies in the pH-responsive Lglutamic acid block which upon protonation is expected to self-assemble into an α-helix.
Ultimately, these α-helices should mimic those discussed in the introduction and disrupt
the integrity of lipid membranes. Figure 23 illustrates the pH-dependence of the coil-tohelix transition for each block copolymer as well as for P1. Not surprisingly, P1 alone
shows no evidence of α-helix structure. However, as the pH is reduced, the CD spectra
indicate pronounced development of α-helices for both P7 (Figure 23-C) and P8 (Figure
23-D); however, P6 with the lowest glutamic acid block length (Figure 23-B) exhibits a
spectrum lacking discernible evidence of helix formation. As the pH is further lowered,
the characteristic signal of the copolymers with longer helical L-Glu blocks becomes
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even more pronounced; eventually, the signal is lost at pH values below 4.5 due to
precipitation and/or onset of flocculation.

Figure 24. MRE as a function of pH for (A) P1, (B) P6, (C) P7, and (D) P8.
Fluorescein Release from POPC Lipid Membranes and Red Blood Cell Hemolysis
Leakage of fluorescent dyes from artificially prepared liposomes is a commonly
used assay to elucidate membrane-particle interactions, and it is widely employed in the
study of antimicrobial peptides/polymers.257–260 This technique is well suited for studying
membrane disruption at endosomal conditions. By varying the pH, the endolytic activity
with respect to α-helical content was investigated using fluorescein loaded 2-oleoyl-1palmitoyl-sn-glycero-3-phosphocholine (POPC) lipids (fPOPC). P6–P8 (200 µg/mL)
copolymers were incubated with fPOPC liposomes for 1 h prior to measurement. Figure
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24 shows the extent of fluorescein release from liposomes as a function of pH P6–P8
copolymer as well as for the HPMA macroinitiator normalized to L-Glu content. No
fluorescein release is observed until pH values are progressively lowered below 6. For P7
and P8, maxima representing 80 % and 70 % release, respectively, occur at pH 5.0; Only
~ 30 % release was observed for P6. These values are consistent with CD data. As the pH
drops, L-glutamate units are converted to α-helix forming L-glutamic acid, and the extent
of fPOPC membrane leakage is related to helical block content.

Figure 25. Fluorescein release from POPC liposomes as a function of pH. fPOPC
liposomes were incubated 1 h with P6 (black), P7 (red), and P8 (cyan). Triton-X100 was
utilized as the positive control. Error bars represent the standard deviation.
The endolytic characteristics of these stimuli-responsive copolymers were also
investigated utilizing a red blood cell hemolysis assay at pH 5.5. Figure 25 shows %
hemolysis as a function of block copolymer concentration, normalized for L-Glu units.
As expected P1 shows no hemolytic activity, while P7 and P8 show notable
concentration-dependent release profiles, reaching values of nearly 90 % after 1 h of
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incubation. On the other hand, P6 which has a much shorter block length displays
substantially lower hemolysis across the concentration range. These results seem to be in
agreement with previous studies indicating a helical block length dependence on
membrane destabilization.236

Figure 26. Percent hemolysis as a function of copolymer concentration at pH 5.5. TritonX100 was utilized as the positive control, and the error bars represent the standard
deviation of triplicate experiments.

Table 1
Molecular weight (Mn, Mw), polydispersity (PDI), composition, conversion, and dn/dc
values for P6–P8 copolymers.
Sample
P2
P6
P7
P8
a

Mn,Tha
(kDa)
30.6
34.8
39.1
42.8

Mn,expb
(kDa)
32.1
37.8
42.1
45.6

Mwb
(kDa)
34.5
44.6
50.5
53.4

PDIb
1.08
1.18
1.20
1.17

Comp
(%)c
100:0
87:13
79:21
65:25

%
conv.d
53
96
98
94

dn/dce
0.170
0.145
0.145
0.144

Theoretical Mn, (Mn,Th), calculated from conversion (ρ) using Mn,Th = ([M]o/[CTA]) x Mw,monomer x ρ + Mw,CTA. bAs determined by

aqueous SEC-MALLS. cAs determined by 1H NMR. dConversions were determined by comparison of the UV signal at 274 nm of the
monomer at t0 to that at tx. eDetermined by Wyatt Optilab DSP interferometric refractometer (λ = 690 nm).
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Section II. Block Ionomer Complexes Consisting of siRNA and Aqueous RAFT
Synthesized Hydrophilic-block-Cationic Copolymers: Monitoring Complex Dissociation
and the Effects on Gene Suppression
Overview
The discovery of siRNA,1 the effector molecule in the RNA interference (RNAi)
pathway in 1998, has resulted in extensive interventive therapy research giving the
potential to regulate nearly any gene of interest.261–263 However, in vitro delivery of
siRNA alone is limited because of enzymatic degradation and lack of cell specificity. As
a result, numerous approaches to more efficient delivery have been investigated.20,264,265
One promising approach capitalizes on the formation of interpolyelectrolyte complexes
(IPECs) between the anionic groups along the phosphodiester backbone and a hydrophilic
cationic polymer.266,267 These IPECs stabilize the RNA from nucleases;41 however, the
molar ratio of cationic to phosphodiester repeating units should be ≈ 1. Nitrogen-tophosphate (N:P) values greater than one lead to non-specific transfection and those less
than one to reduced cellular uptake. Recent advances in controlled polymerization
techniques including RAFT,2,33,268 aRAFT,35,48 ATRP,269 and ROMP270 now allow the
formation of well-defined cationic block copolymers in which block length and
stoichiometry along the IPEC can be “tuned.” These complexes are often referred to as
block ionomer complexes (BICs) and possess a balance of non-complexing hydrophilic
segment(s) and binding segments. A potential advantage of BICs is the reduction of offtarget effects and toxicity.271
The formation of IPECs has been extensively studied and in general, three
parameters constitute complex formation;272,273 hydrogen bonding, hydrophobic effects,
and charge. Poly(ethylene glycol) (PEG) has been shown to form stable complexes with
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proteins at low pH and up to pH 8, and such complexes are formed strictly through
hydrogen bonding.274,275 Hydrophobic interactions are more difficult to ascertain, and the
effects of hydrophobicity are generally manifested in a cooperative fashion.276,277 Xia et
al. demonstrated enhanced binding to lysozyme by introducing a pyrene label to poly(2acrylamido methylpropylsulfate).278 The enhanced biding resulted from interactions
between the probe and lysozyme’s hydrophobic cleft. Interestingly, molecular dynamics
simulations have demonstrated oligonucleotide strand separation when complexed with
weakly interacting charge associations in conjunction with hydrophobic moieties such as
gold nanoparticles.279 IPECs based on charge are most common and are routinely
employed for nucleotide delivery. IPECs prepared via electrostatic associations
consistently maintain a 1:1 stoichiometry, and deviations from 1:1 binding result from
drastic changes in architecture (e.g., branching). Furthermore, regardless of a strong or
weak polyelectrolyte, polyion exchange and substitution readily occur when a small
molecular salt is present.280,281 Ammonium-based polymers (e.g., PEI,19,282 DMAPMA,40–
42

DMAEMA38,39,283) are typically utilized for the cationic block, but polymers possessing

phosphonium groups have also been reported.284–288
To promote efficacious delivery, polymeric vehicles incorporate multiple modes
of interaction. Reineke and co-workers289,290 investigated IPEC formation between
plasmid DNA (pDNA) and poly(glycoamidoamines) (PGAAs). It was determined that
while long-range charge-charge interactions drive IPEC assembly, hydrogen bonding
plays a vital role in stabilizing the complexes. Furthermore, the less dense aminecontaining polymers have stronger electrostatic associations with pDNA.
Our research group has focused on the development of controlled, tailored
(co)polymers afforded via RAFT polymerization, and more specifically, the synthesis of
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these constructs directly in aqueous media. Recent efforts have centered on a rational
design for preparing polymeric drug/gene delivery systems, thus allowing construction of
responsive micelles,117,123,191 theranostics,40 peptide mimics,244 modular copolymers,291,292
and vehicles for endosomal escape.293 We have previously demonstrated targeted delivery
of siRNA via BICs as well as with disulfide-bound amphiphilic copolymers.42,70 In our
experience, we have noted a block-length dependence for efficacious siRNA delivery.41
Although mechanisms for IPEC and BIC formation have been proposed, information
regarding complex dissociation and the role of block length on IPEC stability is lacking.
To our knowledge, this is the first study directed toward elucidating the nature of the
cationic block length with regard to gene suppression utilizing well-defined block
copolymers which form stable, monodisperse BICs with oligonucleotides. Herein, we
report the synthesis of hydrophilic-block-cationic copolymers prepared by aRAFT, and
through the use of a combination of circular dichroism (CD), analytical
ultracentrifugation (AUC), and solution differential scanning calorimetry (DSC),
structural and binding effects on gene suppression with regard to cationic block length
(DMAPMA) were ascertained. Increasing DMAPMA length promotes complex stability
and increases the binding constant. Due to large binding constants, the thermodynamics
of BIC dissociation could not be determined; however, the kinetics of gene suppression
are indicative of an ion exchange/substitution mechanism, providing evidence for a
pathway for siRNA and/or oligonucleotide release in vitro.
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Synthesis of poly(HPMA-stat-APMA) macroCTA, chain extensions with DMAPMA, and
Folic acid conjugation
A statistical macroCTA consisting of a theoretical feed ratio of 95 mol% HPMA
and 5 mol% APMA was prepared via aqueous RAFT polymerization (Scheme 2). The
polymerization was performed in 1 M acetate buffer (0.27 M acetic acid, 0.73 M sodium
acetate, pH = 5.2) at 70 °C using 4-cyanopentanoic acid dithiobenzoate (CTP) and 4,4’azobiscyanovaleric acid (V-501) as the CTA and initiator, respectively. Experimentally
determined compositions for the macroCTA by 1H NMR closely resemble initial feed
ratios which were calculated to be 93 mol% HPMA and 7 mol% APMA.

Scheme 2. Synthetic pathway for the preparation of poly[(HPMA-stat-APMA)-blockDMAPMA] copolymers and subsequent complexation with oligonucleotides.

The resulting poly(HPMA171-stat-APMA13) (P9) macroCTA was subjected to a series of
chain extensions with DMAPMA under similar conditions (Scheme 2). Figure 26
illustrates ASEC-MALLS chromatograms for the macroCTA and these subsequent chain
extensions indicating shifts to lower elution volume, narrow polydispersities (PDI) (<
1.10), and unimodal peaks. Copolymer composition, copolymer molecular weights (Mn
and Mw), PDI, and dn/dc values are presented in Table 2 for P9 and poly[(HPMA-stat-
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APMA)-block- DMAPMA] (P10–P12) copolymers. Copolymer compositions were
determined via 1H NMR by integration of the relative intensities of the methyne-proton
resonance of HPMA at 3.75 ppm to that of the dimethyl proton resonances of DMAPMA
at 2.75 ppm in D2O. The compositions obtained from 1H NMR correlate well with
molecular weights determined via ASEC-MALLS (Figure 25).

Table 2
Molecular weight (Mn, Mw), polydispersity (PDI), composition, conversion (ρ), and dn/dc
values for P1 macroCTA and P2–P4 copolymers.
Sample
P9
P10
P11
P12

Mn,Tha
(kDa)
22.2
27.2
32.4
41.4

Mn,expb
(kDa)
24.0
29.3
33.0
41.5

Mwb
(kDa)
26.4
31.4
35.3
44.4

PDIb
1.10
1.07
1.07
1.07

Comp
(%)c
93:7
80:6:14
71:5:24
59:5:36

%
conv.d
20
14
25
47

dn/dce
0.168
0.167
0.167
0.165

Figure 27. ASEC-MALLS of poly(HPMA-stat-APMA) macroCTA (P9) and subsequent
chain extensions with DMAPMA (P10–P12).
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The pendent, primary amine of APMA conveniently allows for facile conjugation
of electrophilic compounds, and in our case, the cellular targeting moiety, folic acid
(Scheme 2). Conjugation of folic acid was conducted in DMSO at room temperature for
48 h. 1H NMR and UV/vis spectroscopy were used to quantify the folic acid conjugation
for each hydrophilic-block-cationic copolymer (See Appendix), and the content exceeded
92% (~12 out of 13 amines). We are most concerned with the delivery of neutral
complexes (i.e., nitrogen-to-phosphate (N:P) ratio = 1) as excessive cationic charges (N:P
> 1) would encourage universal transfection as well as increase cytotoxicity. With folic
acid pendently conjugated to APMA, allowing for targeted cellular delivery, only the
tertiary amine containing block of DMAPMA will form an electrostatic association with
the chosen oligonucleotide, while the HPMA segments promote water stability,
biocompatibility, and non-immunogenicity. We have chosen aRAFT as it allows for
facile synthesis of tailored architectures with predetermined molecular weights and low
PDIs under mild conditions. Our narrowly dispersed, well-defined, folic acid-conjugated
hydrophilic-block-cationic copolymers are especially suited for formation of
homogeneous block ionomer complexes (BIC) with oligonucleotides, therefore allowing
for the correlation of BIC dissociation to the extent of gene suppression in vitro.

67

Figure 28. Gel electrophoresis of siRNA (Lane 1) and GLuc DNA (Lane 5) as well as
oligonucleotide/copolymer complexes prepared with P2 (Lanes 2 and 6), P3 (Lanes 3 and
7), and P4 (Lanes 4 and 8).
Table 3
The hydrodynamic radii (Rh), polydispersity (PDI), and ζ-potential for siRNA and GLuc
DNA-hydrophilic-block-cationic copolymer complexes.
Sample
siRNA
siRNA-P10
siRNA-P11
siRNA-P12
Gluc DNA
DNA-P10
DNA-P11
DNA-P12

Rh (nm)

PDIa

ζ-potential (mV)

N/A*
18.7
26.3
31.7
N/A*
18.9
26.8
31.8

N/A*
0.206
0.058
0.046
N/A*
0.214
0.064
0.042

-35.1
-2.16
1.35
2.38
-36.2
-2.36
-0.09
1.87

Characterization of hydrophilic-block-cationic/oligonucleotide complexes
We chose to use a double-stranded DNA (dsDNA) which is analogous to siRNA
(vide infra), so complexes formed with DNA should resemble those prepared with RNA
for comparative purposes. Table 3 presents the hydrodynamic radius (Rh), ζ-potential, and
PDI for GLuc/copolymer and siRNA/copolymer complexes. Not surprisingly, both GLuc
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DNA and siRNA complexes increase in size (Rh) with increasing DMAPMA block length
(18–30 nm); interestingly, these systems become more monodisperse with increasing size
(PDIs < 0.2). Typically, intercomplex bridging is observed for larger cationic block
lengths, and we have observed similar phenomena utilizing an analytical ultracentrifuge.
Charge neutrality was confirmed by ζ- potential and gel electrophoresis (Figure 28).
Lanes 2–4 and 6–8 (Figure 28) represent the BICs prepared with either siRNA or GLuc
DNA, respectively; lanes 1 and 5 serve as the siRNA and GLuc DNA controls,
respectively. As can be seen, both DNA and RNA condensation occur while maintaining
charge neutrality, an important requirement which prevents off-target effects and
cytotoxicity. The complexes prepared with GLuc DNA or siRNA are comparable,
monodisperse, and charge-neutral.
Table 4
The maximum, cross-over, and minimum for oligonucleotide and oligonucleotidehydrophilic-block-cationic copolymer complexes.
Sample

λMax (nm)

λCross-over (nm)

λMin (nm)

siRNA

262

253

235

siRNA-P10

263

253

234

siRNA-P11
siRNA-P12

263
266

253
251

234
233

Gluc DNA
DNA-P10
DNA-P11
DNA-P12

272
287
293
299

260
269
271
282

250
254
253
257
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Nucleic acids possess secondary structure alterations of which can be monitored
via circular dichroism (CD).294,295 Typically, B-form (standard, right-handed helix) DNA
possess three CD spectral characteristics: a 280 nm maximum, a 250 nm minimum, and a
260 nm crossover (from positive to negative).212 However, these trends are sequence
dependent. The CD spectrum for GLuc DNA is presented in Figure 29-A (black curve).
Table 4 presents the minimum, maximum, and the crossover for GLuc DNA, siRNA, and
oligonucleotide-hydrophilic-block-cationic copolymer complexes. The GLuc DNA
possesses a 272 nm maximum, a 250 nm minimum, and a 260 nm crossover. These
spectral characteristics drastically shift when complexed with hydrophilic-block-cationic
copolymers, and when complexed with P10, P11, and P12 to form BICs with GLuc
DNA, a red shift in the maximum, crossover, and minimum is observed. Additionally, a
decrease in ellipticity for the maximum and a more negative increase in the ellipticity for
the minimum are observed; these trends exist for all polymers utilized. These changes in
structure are similar to the melt (thermal denaturation) spectra (See Appendix) of GLuc
DNA.

Figure 29. Molar ellipticity of (A) GLuc DNA and DNA-hydrophilic-block-cationic
copolymer complexes, and (B) siRNA and siRNA-hydrophilic-block-cationic copolymer
complexes.
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Alternatively, RNA helices typically exist in the A-form (also right-handed helix),
which possesses a 270 nm maximum, 240 nm minimum, and a 250 nm crossover. Again,
these characteristics are sequence dependent. Figure 29-B depicts the molar ellipticity of
siRNA (Black curve) and siRNA/hydrophilic-block-cationic copolymer complexes (Red,
Blue, and Green curves). The siRNA possesses a 262 nm maximum, a 235 nm minimum,
and a 253 nm crossover. These characteristics remain when siRNA is complexed with
P10, P11, and P12, except a decrease in ellipticity for the maximum and a more negative
increase in ellipticity for the minimum are observed. The changes to siRNA’s spectral
characteristics when bound to P10, P11, and P12 also resemble melting spectra (See
Appendix). We hypothesize that, for both siRNA and GLuc DNA, complexation slightly
denatures the helix to minimize charge repulsion thus stabilizing the block ionomer
complex.
Binding characteristics of Hydrophilic-block-Cationic/GLuc DNA complexes as
determined via analytical ultracentrifugation and solution differential scanning
calorimetry
Analytical ultracentrifugation was conducted to determine characteristics of
complex formation. Utilizing double-stranded DNA (dsDNA), samples were too
polydisperse to accurately determine the binding parameters, therefore the single strands
(sense strand and antisense strand) were utilized for AUC. (Figure 30). P10 (Figure 30A) and P11 (Figure 30-B) were titrated into a fixed amount of ssDNA. From these
titrations, complexation readily occurs as evidenced by shifts to increased apparent
sedimentation (SApparent) values. Furthermore, an association constant may be obtained via
a global fit to a 1:1 stoichiometric model.214 The binding constants related to complex
formation utilizing P10 and P11 were in the range of 104 and 107, respectively, values
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typical for electrostatic association. Although complexation was observed for P10 and
P11, ssDNA titrated with P12 produced polydisperse complexes, and a binding constant
was not determined.

Figure 30. Monitoring the association of single-stranded DNA with hydrophilic-blockcationic copolymers. g(s*) sedimentation coefficient distribution of a titration of ssDNA
with P10 (A) and P11 (B).

DSC measurements of the excess heat capacity relative to a reference cell allow
thermodynamic determinations of dissociation (folded-to-unfolded).296 From these
melting profiles, complex stability can be elucidated. Due to the large amounts of
material required for DSC, utilizing siRNA becomes cost prohibitive. Therefore, a
dsDNA analogue of siRNA was used in all of our DSC studies.
Figure 31 depicts the molar heat capacity (MHC) thermograms, for GLuc DNA
and GLuc DNA/copolymer complexes formed with P2, P3, and P4. The GLuc DNA
duplex dissociation temperature, or melting temperature (Tm), was determined to be 54.4
°C for uncomplexed dsDNA (Figure 31-A). Furthermore, Tm values increased with
DMAPMA block length (P10, 88.4 °C, P11 90.2 °C, P12, 91.8 °C, respectively (Figures
31 B-D). This trend of increasing Tm indicates that polymer complexation significantly
stabilizes the DNA duplex, greater cationic block length conferring greater duplex
stability. These findings are also corroborated by the changes in secondary structure as
observed with CD (Figure 29).
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Figure 31. Molar heat capacity thermograms for (A) GLuc DNA, (B) DNA-P10
complexes, (C) DNA-P11 complexes, and (D) DNA-P12 complexes.

Since the magnitude of the melting endotherm, representing the breaking of
hydrogen bonds between the sense and antisense strands, may mask changes
corresponding to dissociation, ssDNA was separately complexed with hydrophilic-blockcationic copolymers P10–P12. Figure 32 presents the excess heat capacity (ΔCp,XS)
thermograms for copolymer complexes prepared with the sense and antisense strands. For
the scanned temperature range (30 °C–125 °C), no dissociation is observed (i.e., no
exotherm or endotherm) regardless of hydrophilic-block-cationic polymer utilized in
complexation. The absence of dissociation is not surprising, since the binding constants
are so large. A binding constant of 104 would indicate 1/10000 dissociated molecules.
With the concentration used, the dissociated species would be at or below the detection
limit for the calorimeter.
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Figure 32. Excess heat capacity thermograms of hydrophilic-block-cationic copolymer
binding to GLuc antisense and sense strands.

Gene down-regulation
To determine the role of cationic block length on gene suppression, gene downregulation was monitored in KB cells which stably express Gaussia Luciferase. Figure 33
demonstrates the kinetics of gene knockdown as a function of DMAPMA block length.
Increasing the cationic block slightly increases gene suppression as P12 exhibits ~10 %
higher suppression than P10; however, increasing the cationic block also increases the
cytotoxicity (see Appendix). Appreciable cell death occurred with P12 while P10
maintained negligible cytotoxicity over a 48 h period. Interestingly, the observed gene
knockdown maximum is shifted toward longer times when increasing DMAPMA block
length, from 32 h for P10 to 40 h for P12. These shifts in the maxima agree with
literature reports for polyion exchange/substitution rates, since increasing molecular
weight increases the time required for complete ion exchange.280,281,297 Regardless of the
nature of a dissociation or ion exchange/substitution mechanism, the trend is clear—an
increase in binding/stability and the expected increase in time to reach maximum gene
suppression.
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Figure 33. Gene knockdown kinetics for complexes consisting of siRNA and P10 (blue),
P11 (red), and P12 (green). Dharmafect was utilized as the positive control (Black). Error
bars represent the standard deviation of triplicate experiments.

\
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Section III. Characterization of Block Ionomer Complexes Consisting of GQuadruplexes and aRAFT Synthesized Hydrophilic-block-Cationic Copolymers and
Subsequent Polymeric Delivery of AS1411
Overview
Remarkable progress has been achieved in the development of anticancer
therapeutics based on, small interfering RNA (siRNA), antisense oligonucleotides, and
pDNA to name a few. The limiting factors for efficacious delivery of the aforementioned
anticancer biologics are serum stability and reduced cellular internalization. A novel class
of oligonucleotides incorporating G-rich sequences, which fold into G-quadruplexes,
have the innate ability that appear to reduce or eliminate delivery barriers which are
problematic to traditional oligonucleotide drugs. Specifically, AS1411, a 26-mer which
forms a G-quadruplex, has demonstrated in vivo success in Phase I clinical trials in
patients exhibiting metastatic cancer; this anticancer biologic is currently in Phase II
trials. AS1411 inhibits cell proliferation via several possible mechanisms such as
inhibition of shuttling, signal transduction, or modulating mRNA stability, although the
precise mechanism has not been fully elucidated. Nonetheless, AS1411 is an aptamer for
nucleolin, and binding to nucleolin is positively correlated to drug efficacy. To date,
incorporation of AS1411 into polymeric vehicles has been for the purpose of cellular
targeting. Herein, we report the aRAFT synthesis of hydrophilic-block-cationic
copolymers which form stable, monodisperse block ionomer complexes (BICs) with
AS1411. These BICs were well characterized with respect to size (Rh), polydispersity
(PDI), zeta-potential, and structure. From circular dichroism spectroscopy, no alterations
in secondary structure were observed. The drug efficacy of AS1411 is directly correlated
to its ability to bind to nucleolin, and AS1411’s potency was significantly reduced when
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complexed with hydrophilic-block-cationic copolymers. These findings indicate complex
stability plays a vital role in drug efficacy in vitro.

Scheme 3. Synthetic outline for the preparation of poly(HPMA202-stat-APMA8)
macroCTA (P12) and hydrophilic-block-cationic copolymers (P13–P15).

aRAFT polymerization was employed to prepare a poly(HPMA-stat-APMA) macroCTA
(Scheme 3). The polymerization was conducted in acetate buffer (1 M; 0.27 M acetic
acid, 0.73 M sodium acetate) at 70 °C, utilizing 4-cyano-4[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP) and 4,4’-azobiscyanovaleric
acid (V-501) as the CTA and initiator, respectively. The macroCTA was prepared with a
theoretical molar feed ratio of 95:5, agreeing well with measured molar compositions
determined via 1H NMR were 96 mol% HPMA and 4 mol% APMA. The macroCTA P12
was thus determined to be poly(HPMA202-stat-APMA8). Utilizing P12 a series of chain
extensions was performed with DMAPMA (Scheme 3). Table 5 presents the molecular
weight, polydispersity, molar composition, conversion, and dn/dc values for the
macroCTA (P12) and hydrophilic-block-cationic copolymers (P13–P15). From GPC (See
Appendix) successful chain extensions are evident by shifts to lower elution volume as
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well as the monomodal distributions. These results are in agreement with 1H NMR
spectra (See Appendix).
P12 serves two purposes: HPMA confers water stability and APMA provides a
functional handle to conjugate folic acid, a cellular targeting moiety. The incorporation of
DMAPMA (P13–P15) provides cationic segments which electrostatically bind to the
anionic phosphodiester backbone of the G-quadruplex. It is important to note that the
preparation of BICs is formulated with a nitrogen-to-phosphate (N:P) ratio = 1 (i.e.,
neutral complexes) to ensure that off-target effects (i.e., universal transfection) and
cytotoxicity ar minimized. Additionally, these well-defined, monodisperse hydrophilicblock-cationic copolymers allow for precise characterization of BICs prepared with these
copolymers.
Table 5
Molecular weight (Mn, Mw) polydispersity (PDI), molar composition, conversion (ρ), and
dn/dc values for poly(HPMA-stat-APMA) macroCTA (P1) and poly[(HPMA-stat-APMA)block-DMAPMA] (P2–P4) copolymers.
Entry

Mn,Tha
(kDa)

Mn,expb
(kDa)

Mwb
(kDa)

PDIb

Compc
(mol%)

ρd
(%)

dn/dce

P12

28.4

30.2

30.4

1.09

96:4

49

0.168

P13

32.4

32.5

35.1

1.06

86:4:10

11

0.167

P14

35.5

36.4

38.8

1.06

78:4:18

21

0.167

P15

42.0

43.3

46.3

1.07

68:2:30

40

0.166

Theoretical Mn, (Mn,Th), calculated from conversion (ρ) using Mn,Th = ([M]o/[CTA]) x Mw,monomer x ρ + Mw,CTA. bAs determined by

a

aqueous SEC-MALLS. cAs determined by 1H NMR. dConversions were determined by comparison of the UV signal at 274 nm of the
monomer at t0 to that at tx. eDetermined by Wyatt Optilab DSP interferometric refractometer (λ = 690 nm).
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Figure 34. Circular dichroism spectra of AS1411 and AS1411/hydrophilic-block-cationic
copolymer complexes.

Table 6
The hydrodynamic radii (Rh), polydispersity, and zeta-potential for AS1411 and AS1411hydrophilic-block-cationic copolymer complexes.
Sample

Rh (nm)

PDIa

ζ-potential (mV)

AS1411

N/A*

N/A*

-11

AS1411-P13

19

0.047

-2.16

AS1411-P14

21

0.064

1.35

AS1411-P15

28

0.051

2.38

*The scattering intensity was too low for an accurate determination. aThe PDI was determined at 90°.

G-quadruplex formation can be monitored via Uv-Vis spectroscopy (See Appendix). At
room temperature the oligonucleotide is folded into a quadruplex, and by heating the
sample above the melting temperature (Tm), the oligonucleotide unfolds. By subtraction
of the absorbance scan at room temperature from the absorbance scan above theTm, a
characteristic difference spectrum can be obtained. This difference spectrum exhibits an
isobestic point at 280 nm, a net hyperchromism above 285 nm, and a maximum at 295
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nm; however, these characteristics are dependent upon oligonucleotide sequence,
flanking sequences, and cationic counterion used. Difference spectra were recorded for
AS1411. The spectral characteristics for AS1411 determined via Uv agree with literature
reported characteristics, exhibiting a 295 maximum, 280 nm isobestic point, and a net
hyperchromism. While Uv-Vis spectroscopy is a facile method for ascertaining
quadruplex formation, this method proves difficult when utilizing BICs. Polymer
complexation significantly increases the Tm (~40 °C), and the temperature required for
denaturation of the quadruplex is above the boiling point of water. Nevertheless, circular
dichroism spectroscopy (CD) can provide necessary insight into structural modifications
of AS1411. Utilizing CD, parallel quadruplexes are characterized by the presence of a
peak at 264 nm and a trough at 240 nm. Figure 34 presents the CD spectra for AS1411
and AS1411/hydrophilic-block-cationic copolymer complexes. AS1411 (Figure 34, black
curve) presents a typical CD spectrum indicative of a parallel G-Quadruplex. Upon
complexation no noticeable shifts in the characteristic peaks are observed (See Appendix
for λmax, λmin, and λcross-over); In contrast, we have previously demonstrated red shifting
when hydrophilic-block-cationic copolymers are complexed with double-stranded DNA
and RNA, B-form and A-form, respectively. Two other G-quadruplex forming sequences
were also utilized (See Appendix), and similar results were obtained when complexed
with hydrophilic-block-cationic copolymers.
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Figure 35. Confocal images of AS1411 (positive control) and P15/AS1411 BICs. The
nucleus was stained with DAPI, and the 5’-end of AS1411 was labeled with Cy3.
To reduce universal transfection, BICs were prepared with a N:P = 1. Table 6 presents the
hydrodynamic radii (Rh), polydispersity (PDI), and zeta-potential for AS1411 and
AS1411/hydrophilic-block-cationic copolymer complexes. From zeta-potential,
complexes prepared with P13–P15 exhibit near-neutral values. Additionally, BICs are
monodisperse, and the Rh increases with increasing DMAPMA block length; P13 = 19
nm, P14 = 21 nm, and P15 = 28 nm.
Cellular entry was monitored via confocal microscopy (Figure 35). Since AS1411
enters the cells naturally, typically by macropinocytosis, it was used as the positive
control; AS1411 was labeled with CY3, and the nucleus was stained with DAPI. From
Figure 35-middle row, AS1411, alone, successfully enters KB cells. Utilizing P15 as the
drug carrier, cellular delivery is also achieved. Notably, signals from the CY3
fluorophore are present in both the cytoplasm and nucleus; similar results are also
witnessed when utilizing P13 and P14 (data not shown).
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Figure 36. Cytotoxicity of AS1411 and BICs of AS1411 and P12, P14, and P15 after 48
h and 72 h. Error bars represent the standard deviation of triplicate experiments.

Having achieved cellular delivery and entry, the anti-proliferative capability was
assessed via cell viability assays (Figure 36). The concentration of AS1411 was
maintained at 5 μM. After 48 h (Figure 36), negligible activity occurs, achieving a ~ 15%
reduction in cell density. After 72 h, a ~65% reduction is observed. Interestingly,
polymeric delivery of AS1411 using P13, P14, and P15 achieve dissimilar results. After
48 h, P13, P14, and P15 display negligible anti-proliferative activity. Additionally, after
72 h, between 20–25% in cellular reduction is observed when using P13, P14, and P15.
We have previously reported time-delays in maximizing gene suppression utilizing
siRNA. It is likely that the potency of AS1411 is reduced when delivered with
hydrophilic-block-cationic copolymers due to the increased stability provided when the
G-quad is complexed (i.e., decomplexation requires ion exchange/substitution reactions),
thus delivery of this anticancer biologic would necessitate an increased amount of time
before modest drug activity can be observed, since the activity of AS1411 is presumed to
not be catalytic.
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CHAPTER V
CONCLUSIONS
Section I. Endolytic, pH-Responsive HPMA-b-(L-Glu) Copolymers Synthesized via
Sequential Aqueous RAFT and Ring Opening Polymerizations
HPMA-block-(L-Glu) copolymers with controlled structures, narrow PDIs, and
target molecular weights were prepared by sequential aqueous RAFT and ring opening
(NCA) polymerizations followed by post-reaction hydrolysis. The block copolymers with
tailored L-glutamic acid sequences allow formation of membrane-disruptive helical
segments at biorelevant pH values. Red blood cell hemolysis and fPOPC release studies
were performed, and at moderate concentrations and sufficient block lengths (α-helical
content), pH-dependent hemoglobin and fluorescein release occurred. It is anticipated that
the facile synthetic approach reported here will allow further development of modular
drug/gene carriers for the efficient endosomal release of anticancer drugs. While we have
shown membrane disruption with these novel HPMA-block-(L-Glu) copolymers, future
studies will be necessary to evaluate efficiency and mechanistic pathways of drug/gene
delivery in vitro.
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Section II. Block ionomer complexes consisting of siRNA and aqueous RAFT
synthesized hydrophilic-block-cationic copolymers: Monitoring complex dissociation
and the effects on gene suppression
Aqueous RAFT was utilized to prepare poly[(HPMA-stat-APMA)-blockDMAPMA copolymers with controlled lengths of DMAPMA. Well-defined BICs were
prepared with siRNA and its dsDNA analogue, and the complexes formed with siRNA
and GLuc DNA were comparable. AUC demonstrated increased binding constants with
increasing cationic (DMAPMA) block length. Solution differential scanning calorimetry
was conducted to determine BIC stability. The melting temperature of GLuc DNA, the
siRNA analogue, significantly shifted to higher temperatures when complexed with
hydrophilic-block-cationic copolymers. Furthermore, increasing DMAPMA block length
increased the Tm of each block ionomer complex (P12 > P11 > P10). Since thermal
denaturation of the DNA provided a large endotherm, single-stranded DNA was
complexed with hydrophilic-block-cationic copolymers to determine thermodynamics of
dissociation. Since no complex dissociation was observed under our experimental
conditions, we believe that the binding constants are so high that any species dissociation
would be below the instruments detection capability. While the precise nature of BIC
complexation/decomplexation is not fully understood, these studies clearly demonstrate
an increase in gene suppression with increasing DMAPMA block length, and more
importantly, longer DMAPMA block lengths produced a time-delay in achieving a gene
knockdown maximum. Additionally, the kinetics for achieving these maxima are
consistent with ion exchange/substitution rates for IPECs and BICs. While we have
demonstrated the effect of block length on gene suppression, the effect of the cationicanionic registry (i.e., arrangement of cationic charges along the phosphate-helix
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backbone) on binding strength, and subsequently, gene suppression is still under
investigation.
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Section III. Characterization of Block Ionomer Complexes Consisting of GQuadruplexes and aRAFT Synthesized Hydrophilic-block-Cationic
Copolymers and Subsequent Polymeric Delivery of AS1411
aRAFT was utilized to prepare poly[(HPMA-stat-APMA)-block-DMAPMA]
copolymers with increasing DMAPMA block length (P13–P15). The HPMA segments
confer water stability, while APMA provides a conjugation site for folic acid, a cellular
targeting moiety. The cationic tertiary amines of DMAPMA serve to bind to AS1411, a
G-quadruplex biologic, to form BICs. These complexes were well characterized; the
hydrodynamic radii (Rh) increases with increasing DMAPMA block length (P15 > P14 >
P13) and the complexes displayed near neutral zeta-potential values. Additionally, these
complexes maintained narrow polydispersities (PDIs < 0.1). Circular dichroism
spectroscopy (CD) was employed to ascertain structural alterations upon hydrophilicblock-cationic copolymer binding to AS1411. Polymer binding produces no observable
shifts in the CD spectra, indicating structural modifications do not occur when AS1411 is
complexed. The anti-proliferative capability of AS1411 was assessed by monitoring KB
cell viability. KB cell proliferation was observed after 48 h, but ~ 65 % reduction in
proliferation was achieved after 72 h when utilizing AS1411. BICs were less effective,
achieving 20–25 % reduction in proliferation after 72 h. We hypothesized that complex
stability for these BIC systems warrants a much longer time required for complex
dissociation (e.g., ion exchange/substitution) to occur. Further studies are ongoing to
probe the relationships between complex stability and AS1411’s in vitro potency.
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CHAPTER VI
FUTURE RECOMMENDATIONS
The work presented in this dissertation has provided novel insights into
overcoming polymeric drug/gene delivery barriers. We have demonstrated that siRNA
release is dictated via an ion exchange/substitution pathway, and exploiting this pathway,
the time to achieve a gene suppression maximum has the potential to be tailored. We have
only demonstrated this phenomenon utilizing polymeric carriers equipped with
protonated tertiary amines. To explore further into these structure-property relationships,
it is recommended that two systematic studies be conducted to elucidate effects imposed
by the cationic structure: One study to vary the amine (cation) type, and the second study
to vary the cationic charge density.
Scheme 4 presents a proposed synthetic pathway to study structure-property
relationships relative to amine type. This synthetic strategy builds upon the McCormick
group expertise in preparing functional, modular (co)polymers. Flores et al. demonstrated
successful RAFT polymerization of unprotected isocyanates; however, these polymers
could not be purified, and they required immediate functionalization. In this synthetic
strategy, the isocyante is protected with an imidazole group, which can be easily
displaced (i.e., quantitatively) with nucleophiles. More importantly, this pathway allows
for the total block length to be equal, thus studying each amine type will relate to the
ionic strength of the amine. Since the cationic block remains the same, only the binding
strength between each type of amine will differ, and therefore, increased ionic strength
would, hypothetically, increase the time required for complete dissociation and
subsequently, gene suppression; refer to Section II of Chapter IV.
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Scheme 4 Proposed synthetic pathway to synthesize block copolymers with differing
amines (1°–4°).
In the second study, charge density is the focus. Scheme 5 presents a synthetic
method that allows for production of polymeric carriers that vary in charge density. It is
anticipated that a charge density exists such that dissociation may be monitored directly.
To begin, the macroCTA remains similar to previous reports, and charge separation is
achieved via increasing the molar composition of HPMA during chain extensions with a
cationic monomer; see Table 7 for proposed molar compositions.
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Scheme 5. Proposed synthetic pathway for the preparation of poly[(HPMA-stat-APMA)block-(HPMA-stat-DMAPMA)] copolymers. In this method, The HPMA molar content
in the chain extension will be varied to ensure charge separation (i.e., reduced charge
density).

Table 7
Proposed hydrophilic-block-cationic copolymer compositions and degree of
polymerization.
HPMA-stat-Folate Block
(w:x)

HPMA-stat-Cationic Block
(y:z)

Total Cationic
Repeats (DP)

95:5

0:100, 10:90, 20:80, 30:70, 40:60,
50:50, 60:40, 70:30, 80:20, 90:10,
100:0

Maintained at
25
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The final study aims to determine enzymatic interactions with BICs and enzymes. This
study has two purposes. The first purpose is to elucidate kinetics of BIC ion
exchange/substitution, and the second purpose is to ascertain the inhibition mechanisms
(i.e., are hydrophilic-block-cationic copolymers competitive or noncompetitive inhibitors
and are they reversible).
Consider the following scenario presented in Scheme 6. This scheme describes the
formation of hydrophilic-block-cationic (HbC)-siRNA BICs which will undergo an
irreversible exchange reaction with an analogous dsDNA. This exchange reaction is
irreversible since an RNase will be present to selective cleave the siRNA into
mononucleotides. It should be noted that human RNases are not capable of
mononucleotide cleavage, and the RNase used should be purchased from EpiBio
(Ribboshredder™-RS12100).

Scheme 6. Proposed reaction method for the determination of BIC ion
exchange/substitution kinetics, and the inhibition mechanism.
Utilizing a photodiodearray spectrophotometer equipped with a stop-flow cuvette,
the kinetics of BIC ion exchange/substitution as well as the inhibitory mechanisms may
be elucidated. One will directly observe the formation of siRNA mononucleotides via an
increase in absorbance at 260 nm. From this absorption increase kb may be determined.
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The challenge in this design arises from the fact that nucleases obey Michaelis-Menten
kinetics, represented as kMMK in the above scheme. A brief overview of enzyme kinetics
is supplied, but any introductory biochemistry text will present the derivation of
Michaelis-Menten equation in detail. An enzyme E combines with substrate S to form an
ES complex, with a rate constant k1. ES can dissociate to E and S, with a rate constant of
k-1, or ES can proceed to form product P, with a rate constant of k2 (See Equation 3).

(eq 3)

The ES complex can also be reformed from E and P by the reverse reaction with a rate
constant k-2. However, one may simplify these reactions by considering the rate of
reaction at times close to zero when there is negligible product formation, thus no reverse
reaction (i.e., k-2[P] ≈ 0) (See Equation 4):

(eq 4)

The rate of reaction at times close to zero is determined by V0, and it is determined for
each substrate concentration by measuring the rate of product formation (siRNA
mononucleotides) at early times, typically within the beginning 5 % of the reaction. V0
can be related to the rate of catalysis to the concentrations of substrate and enzyme and
the rate of the individual steps via the steady-state approximation to give Equation 5
(eq 5).
Equation 8 is simplified by defining a new constant, KM, called the Michaelis constant:
(eq 6).
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After rearranging and solving for [ES], the equation becomes
(eq 7).
Since the substrate concentration is usually present at a much higher concentration than
the enzyme, the concentration of uncombined substrate [S] is very nearly equal to the
total substrate concentration. Furthermore, the concentration of uncombined enzyme [E]
is equal to the total enzyme concentration minus the concentration of the ES complex.
Using this information,V0 may be determined utilizing Equation 8:
(eq 8)
in which Vmax = k2[E]T, and [E]T is the total enzyme concentration. Equation 10 is known
as the Michaelis-Menten equation.

Figure 37 Enzyme kinetic plots representing typical Michaelis-Menten kinetics (A) and a
Lineweaver-Burk plot (B).

This equation is important for two reasons, the equation describes the first order
reaction rate (i.e., at early times [S] << KM, V0 = (Vmax/KM)[S])) as well as the zero order
reaction rate when [S] >> KM (V0 = Vmax) (See Figure 37-A). Since one may determine
Vmax, and the total enzyme concentration is known, then the rate of catalysis k2 may be
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determined, and in our case, k2 = KMMK (See Scheme 6). It should be noted that there are
two methods for the determination of Michaelis-Menten parameters. The first method
utilizes a double reciprocal plot — the Lineweaver-Burk plot (See Equation 9 and Figure
37-B).
(eq 9)
This plot yields a straight line with a y-intercept of 1/Vmax and a slope of KM/Vmax. The xintercept is -1/KM. This method is not recommended as a means to determine the
Michaelis-Menten parameters because it overestimates the x-intercept and overestimates
the slope. In the second method, a double-floating parameter fit is applied to the
Michaelis-Menten kinetic data. This procedure is easily accomplished utilizing Origin or
GraphPad Prism graphing software, and in the case of enzyme kinetics, the equations and
fitting function are built-in. This method is the most accurate means to determine the
Michaelis-Menten parameters.

Figure 38. Data representative of competitive inhibition.
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The determination of k2 allows for the determination kb which is the rate of BIC
ion exchange/substitution. Once the rate of BIC exchange/substitution is known, the
inhibitory mechanism may be ascertained. This section will provide a means to determine
reversible inhibitors.
There are three types of reversible inhibitors (See Scheme 7), competitive,
uncompetitive, and noncompetitive. In competitive inhibition (See Figure 38), the
inhibitor competes with the substrate for the active site. The dissociation constant for the
inhibitor (Ki) is given by Equation 10
(eq 10)
in which [E] is the enzyme concentration, [I] is the inhibitor, and in our case, the
hydrophilic-block-cationic copolymer utilized, and [EI] is the concentration of enzymeinhibitor complex. The smaller the Ki, the more potent inhibition. The effect of a
competitive inhibitor is to increase the apparent value of KM. This new value of KM,
called KM, APP, is determined via Equation 11.
(eq 11)
In uncompetitive inhibition (See Figure 39), the inhibitor binds only to the ES
complex. This enzyme-substrate-inhibitor complex ESI (i.e., BICs interacting with
enzyme) does not go on to form any product thus lowering Vmax. For uncompetitive
inhibition, a lower concentration of S is required to form half the maximal concentration
of ES, and the apparent value of KM is reduced.
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Scheme 7. Reaction pathways for competitive, noncompetitive, and uncompetitive
inhibition.

In noncompetitive inhibition (See Figure 40), substrate can bind to the enzymeinhibitor complex; however, the enzyme-inhibitor-substrate complex does not proceed to
form product. The value of Vmax is decrease to a new value, Vmax,app, and the value of KM
is unchanged. Vmax,app can be determined from Equation 12.

Figure 39. Data representative of uncompetitive inhibition.
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(eq 12)

Noncompetitive inhibition results in solutions that behave similarly to a dilute
concentration of functional enzyme, thus the lowering of Vmax is observed while KM is
unaltered.
The most facile method to ascertain the inhibitory mechanism is via doublereciprocal plots (See Figure 41). In competitive inhibition, the y-intercept remains
unchanged; however, the slope is increased. In the presence of a competitive inhibitor,
Equation 8 is replaced by Equation 13 (See Figure 41-B).
(eq 13)
In uncompetitive inhibition, the inhibitor combines only with the enzymesubstrate complex. Therefore, Equation 10 is replaced with Equation 16 (See Figure 41C).
(eq 14)

Figure 40. Data representative of noncompetitive inhibition.
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In noncompetitive inhibition, the value of Vmax is decreased to the new value Vmax,app, and
the y- intercept is increased. The new slope, which is equal to KM/Vmax,app, is increased by
the same factor (See Figure 41-D).
From these plots, the inhibitory mechanism may be ascertained.

Figure 41. Representative double-reciprocal plots for Lineweaver-Burk (A), competitive
inhibition (B), uncompetitive inhibition (C), and noncompetitive inhibition (D).
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APPENDIX A
SUPPLEMENTARY TO SECTION I OF CHAPTER IV

Figure A1 Absorbance of ninhydrin at 570 nm versus amine concentration for D-alanine
(filled circles) and P2 (open, blue square).

Figure A2. Fluorescence intensity of fPOPC at pH 7.4. fPOPC was incubated with P1 and
P6–P8 copolymers. Triton-X100 was utilized as the positive control. No observable
increase in fluorescein release was determined at pH 7.4 when incubated with P6–P8
copolymers.
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Figure A3. Percent hemolysis release as a function of concentration for P1 and P6–P8
copolymers. Triton-X100 was utilized as the positive control.
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APPENDIX B
SUPPLEMENTARY TO SECTION II OF CHAPTER IV

Figure B1. 1H NMR of P9, P10, P11, and P12 (the macroCTA and subsequent chain
extensions with DMAPMA).
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Figure B2. Circular dichroism melting spectra of GLuc DNA.

Figure B3. Circular dichroism melting spectra for siRNA.
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Figure B4. Heating and cooling solution DSC thermograms for (A) GLuc DNA, (B)
hydrophilic-block-cationic copolymers (P10–P12), and (C) DNA-hydrophilic-blockcationic copolymer complexes. No hysteresis is evident between heating and cooling (i.e.,
these systems are reversible).
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Figure B5. Solution DSC thermograms illustrating the scan rate dependence for (A)
GLuc DNA, (B) DNA-P10 complexes, (C) DNA-P11 complexes, and (D) DNA-P12
complexes. The melting temperature (Tm) remains constant with respect to scan rate (i.e.,
these systems are in equilibrium).
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Figure B6. Cell viability assays of P10, P11, and P12.

Table B1
The melting temperature (Tm) calorimetric enthalpy (ΔHCal), van’t Hoff enthalpy (ΔHVH),
entropy (ΔS) Gibb’s free energy (ΔG) for GLuc DNA and GLuc DNA-hydrophilic-blockcationic copolymer complexes.
Sample
Gluc DNA
DNA-P10
DNA-P11
DNA-P12

ΔHCal
(kcal/mol)
240
420
483
461

ΔHVH
(kcal/mol)
240
367
686
1900

ΔS
(kcal/mol *K)
106
120
140
143

ΔG
(kcal/mol)
204
340
413
393

Tm (°C)
54.4
88.8
90.2
91.8
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APPENDIX C
SUPPLEMENTARY TO SECTION III OF CHAPTER IV

Figure C1. Light scattering traces of poly(HPMA202-stat-APMA8) macroCTA (P1), and
subsequent chain extensions with DMAPMA (P2–P4).
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Figure C2. 1H NMR of poly(HPMA202-stat-APMA8) macroCTA (P1) and subsequent
chain extensions with DMAPMA (P2–P4).

Figure C3. Uv/Vis spectroscopy of conjugated folic acid to P2, P3, and P4.
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Figure C4.Heated (Red), cooled (Black), and difference (Blue, dashed) Uv/vis spectra of
(A) 15APT, (B) 27S, and (C) AS1411 G-quadruplexes.
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Figure C5. Circular dichroism spectra of 27S and hydrophilic-block-cationic
copolymer/27S BICs.

Table C1
The maximum, minimum, and cross-over for AS1411 and hydrophilic-block-cationic
copolymer/AS1411 BICs.
Sample

λMax (nm)

λMin (nm)

λCross-over (nm)

AS1411
P2-AS1411
P3-AS1411
P4-AS1411

261
261
261
261

238
239
238
239

252
255
253
255
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Table C2
The maximum, minimum, and cross-over for 27S and hydrophilic-block-cationic
copolymer/27S BICs.
Sample

λMax (nm)

λMin (nm)

λCross-over (nm)

27S
P2-27S
P3-27S
P4-27S

264
264
264
264

241
241
241
241

251
250
252
255
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